1
|
Schiavone M, Gasperetti A, Laredo M, Breitenstein A, Vogler J, Palmisano P, Gulletta S, Pignalberi C, Lavalle C, Pisanò E, Ricciardi D, Curnis A, Dello Russo A, Tondo C, Badenco N, Di Biase L, Kuschyk J, Biffi M, Tilz R, Forleo GB, Arosio R, Ruggiero D, Viecca M, Ziacchi M, Diemberger I, Angeletti A, Fierro N, Della Bella P, Mitacchione G, Compagnucci P, Casella M, Santini L, Piro A, Picarelli F, Bressi E, Calò L, Montemerlo E, Rovaris G, De Bonis S, Bisignani A, Bisignani G, Russo G, Guarracini F, Vitali F, Bertini M, Fink T, Fastenrath F, Kaiser L, Hakmi S, Waintraub X, Gandjbakhch E, Saguner A. Inappropriate Shock Rates and Long-Term Complications due to Subcutaneous Implantable Cardioverter Defibrillators in Patients With and Without Heart Failure: Results From a Multicenter, International Registry. Circ Arrhythm Electrophysiol 2023; 16:e011404. [PMID: 36595631 DOI: 10.1161/circep.122.011404] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Affiliation(s)
- Marco Schiavone
- Luigi Sacco University Hospital, Milan (M.S., A.G., G.B.F.).,Department of Systems Medicine, University of Rome Tor Vergata, Italy (M.S.)
| | - Alessio Gasperetti
- Luigi Sacco University Hospital, Milan (M.S., A.G., G.B.F.).,Department of Cardiology, Johns Hopkins University, Baltimore, MD (A.G., N.B.)
| | - Mikael Laredo
- APHP, Hôpital Pitié Salpêtrière, Paris, France (M.L.)
| | | | - Julia Vogler
- Department of Elctrophysiology, Herzzentrum Lubeck, Germany (J.V., R.T.)
| | - Pietro Palmisano
- Cardiology Unit, "Card. G. Panico" Hospital, Tricase, Italy (P.P.)
| | - Simone Gulletta
- Arrhythmology & Electrophysiology Unit, San Raffaele Hospital, IRCCS, Milan (S.G.)
| | | | | | - Ennio Pisanò
- U.O.S.V.D. Cardiac Electrophysiology - "V. Fazzi" Hospital, Lecce (E.P.)
| | | | | | - Antonio Dello Russo
- Cardiology and Arrhythmology Clinic, University Hospital "Umberto I-Salesi-Lancisi," Ancona (A.D.R.)
| | - Claudio Tondo
- Heart Rhythm Centre, Monzino Cardiology Centre, IRCCS, Milan, Italy (C.T.)
| | - Nicolas Badenco
- Department of Cardiology, Johns Hopkins University, Baltimore, MD (A.G., N.B.)
| | - Luigi Di Biase
- Cardiac Arrhythmia Center, Division of Cardiology at Montefiore-Einstein Center, Bronx, NY (L.D.B.)
| | - Jürgen Kuschyk
- Cardiology Unit, University Medical Center Mannheim, Germany (J.K.)
| | - Mauro Biffi
- Cardiology, IRCCS, Department of Experimental, Diagnostic & Specialty Medicine, Sant'Orsola Hospital, University of Bologna, Bologna, Italy (M.B.)
| | - Roland Tilz
- Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), Partner Site Hamburg/Kiel/Lübeck, Lübeck, Germany (R.T.)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Ameri P, Schnabel RB, Pecen L, Diemberger I, Gwechenberger M, Siller-Matula J, Kirchhof P, De Caterina R. Two-year outcomes of patients with atrial fibrillation and heart failure: the ETNA-AF-Europe registry. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.619] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Heart failure (HF) is an established risk factor for stroke and systemic embolic events (SEE) in subjects with atrial fibrillation (AF), but it is debated whether this risk varies according to left ventricular ejection fraction (LVEF).
Methods
We investigated the impact of HF in the ETNA-AF-Europe registry, a prospective, multi-centre, post-authorisation, observational study enrolling patients treated with edoxaban for AF in 825 sites from 10 European countries. This 2-year follow-up analysis is based on a data snapshot from 26 October 2020. HF was defined as a) history of HF or b) ischaemic cardiomyopathy or c) EF <40% or d) dyspnoea not due to chronic obstructive pulmonary disease together with ≥1 of the following: ischaemic heart disease, valvular heart disease, or hypertension treated with ≥3 drugs. Patients' characteristics are summarised descriptively and clinical outcomes are reported as annualised event rates. The hazard ratio (HR) with 95% confidence intervals (CI) for the association of HF with the outcomes was assessed in Cox regression models with stepwise variable selection.
Results
Of the 13,133 patients, 1,854 (14.1%) had HF; LVEF was available for 1,489 (80.3%), and was <40% in 671 (43.9%) and ≥40% in 857 (56.1%). Patients with HF were more often men and slightly older than those without (Table 1). As expected, they also had more cardiovascular (CV) comorbidities and higher CHA2DS2-VASC and, to a lesser extent, HAS-BLED scores (Table 1). At the end of the 2-year follow-up, the rates of ischaemic stroke/transient ischaemic attack (TIA)/SEE, major bleeding, intracranial haemorrhage (ICH), CV death, and all-cause death were higher in patients with than without HF (Figure 1).
When patients with HF were categorized according to LVEF, ischaemic stroke/TIA/SEE was more frequent in those with LVEF ≥40% vs those with LVEF <40%. By contrast, more patients with LVEF <40% died due to any as well as CV causes. The rates of major bleeding and ICH were comparable between the two subgroups (Figure 1).
Univariable Cox regression analysis confirmed the association of HF with major bleeding (HR 2.01, 95% CI [1.49–2.71]) and all-cause death (2.62 [2.28–3.02]), but not with ischaemic stroke/TIA/SEE (1.06 [0.72–1.55]). The results were consistent when LVEF was taken into account: the HRs for LVEF <40% or LVEF ≥40%, respectively, were 1.60 (0.99–2.60) and 1.55 (1.02–2.38) for major bleeding, 2.11 (1.69–2.63) and 1.59 (1.28–1.97) for all-cause death, and 0.66 (0.31–1.41) and 1.19 (0.71–1.98) for ischaemic stroke/TIA/SEE.
Conclusions
In this real-world, large cohort of patients with AF on edoxaban, those with HF at baseline faced more ischaemic, bleeding, and death events, and having HF increased the risk of major bleeding and death, with no differences according to LVEF.
Funding Acknowledgement
Type of funding sources: Private company. Main funding source(s): This research was funded by Daiichi Sankyo Europe.
Collapse
Affiliation(s)
- P Ameri
- University of Genova, Department of Internal Medicine , Genova , Italy
| | - R B Schnabel
- University Heart & Vascular Center Hamburg, Department of Cardiology , Hamburg , Germany
| | - L Pecen
- The Czech Academy of Sciences, Institute of Computer Science , Prague , Czechia
| | - I Diemberger
- University of Bologna, Department of Experimental, Diagnostic and Specialty Medicine - DIMES , Bologna , Italy
| | - M Gwechenberger
- Medical University of Vienna, Division of Cardiology, Department of Internal Medicine II , Vienna , Austria
| | - J Siller-Matula
- Medical University of Vienna, Division of Cardiology, Department of Internal Medicine II , Vienna , Austria
| | - P Kirchhof
- University Heart & Vascular Center Hamburg, Department of Cardiology , Hamburg , Germany
| | - R De Caterina
- University of Pisa, Chair of Cardiology , Pisa , Italy
| |
Collapse
|
3
|
De Vries TAC, Pecen L, Komen JJ, Diemberger I, Fumagalli S, De Groot JR, Kirchhof P, De Caterina R. Perceived frailty and clinical outcomes in men and women with atrial fibrillation treated with edoxaban: insights from the 2-year follow-up of ETNA-AF-Europe. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2544] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
Background/Introduction
Many clinicians estimate the frailty of patients solely using their clinical expertise instead of validated scores. Previous reports show that women are more often perceived as frail than men. It is uncertain whether the same trend is observed in patients with atrial fibrillation (AF) and if the association between perceived frailty and adverse clinical outcomes is affected by sex.
Purpose
To assess whether sex affects the association between frailty status and adverse clinical outcomes in patients with AF.
Methods
ETNA-AF-Europe is an ongoing, post-authorisation, prospective cohort study conducted in 825 centres enrolling patients with AF treated with edoxaban in 10 European countries. In this substudy on the first 2-years of follow-up, patients were categorised in four subgroups based on sex and clinician-perceived frailty at baseline. We calculated incidence rates (per 100 patient-years) of the composite endpoint of any stroke or systemic embolic event (SEE), of major bleeding, and of all-cause death for the four subgroups; and determined the unadjusted association between perceived frailty (frail vs non-frail) and each outcome, stratified by sex, using Cox proportional hazards models. To assess for consistency in our findings, we tested the same associations by sex category but using objective risk factors: age (>74 vs <65 years) and CHA2DS2-VASc score (≥4 vs <4).
Results
Information about frailty-status was recorded for 12,254 (93.3%) patients, of whom 8.5% of men and 15.4% of women were perceived as frail by their clinician (p<0.0001) (Table 1). For both sex categories calculated separately, the risk of any stroke or SEE, major bleeding, or all-cause death was higher in the frail than in the non-frail patients (Figure 1A). However, the difference in risks of stroke or SEE between frail and non-frail patients was greater for men (HR 3.77, 95% confidence interval [CI] 2.25–6.31) than for women (HR 2.18, 95% CI 1.34–3.55) and a similar trend toward a greater risk-difference for men was seen for the risk of all-cause death (HR 4.58, 95% CI 3.76–5.59 vs HR 3.63, 95% CI 2.94–4.49). There was no marked difference between sex categories in the association between frailty-status and major bleeding (HR 2.86, 95% CI 1.81–4.50 vs HR 2.56, 95% CI 1.68–3.90) (Figure 1A). The association of age or CHA2DS2-VASc subgroups with clinical outcomes were either similar between sexes or suggested a possible lower risk-difference for men (Figure 1B and 1C).
Conclusion
In our cohort, differences in the risks of clinical outcomes between those who were perceived as frail and those who were not is more pronounced for men than women. Because we did not observe similar trends in the associations between age or CHA2DS2-VASc score subgroups and clinical outcomes, our results indicate that clinicians perceive the extent of frailty differently in men than in women.
Funding Acknowledgement
Type of funding sources: Private company. Main funding source(s): This research was funded by Daiichi Sankyo Europe.
Collapse
Affiliation(s)
- T A C De Vries
- Amsterdam University Medical Center, Department of Cardiology , Amsterdam , The Netherlands
| | - L Pecen
- The Czech Academy of Sciences, Institute of Computer Science , Prague , Czechia
| | - J J Komen
- Daiichi Sankyo Netherlands , Amsterdam , The Netherlands
| | - I Diemberger
- University of Bologna, Department of Experimental, Diagnostic and Specialty Medicine – DIMES , Bologna , Italy
| | - S Fumagalli
- University of Florence, Department of Experimental and Clinical Medicine , Florence , Italy
| | - J R De Groot
- Amsterdam University Medical Center, Department of Cardiology , Amsterdam , The Netherlands
| | - P Kirchhof
- University Heart & Vascular Center Hamburg, Department of Cardiology , Hamburg , Germany
| | - R De Caterina
- University of Pisa, Chair of Cardiology , Pisa , Italy
| |
Collapse
|
4
|
Boriani G, Diemberger I, Pisano' ECL, Pieragnoli P, Locatelli A, Capucci A, Talarico A, Zecchin M, Rapacciuolo A, Piacenti M, Indolfi C, Arias MA, Checchinato C, D'Onofrio A. Influence of obesity and overweight on the association between sleep-disordered breathing and atrial fibrillation: the DASAP-HF study. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.530] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
The association between sleep apnea (SA) and atrial fibrillation (AF) has been well described. However, it remains unclear whether the association is causative or primarily dependent on shared comorbidities such as obesity. The Respiratory Disturbance Index (RDI) computed by an implantable cardioverter defibrillator (ICD) algorithm accurately identifies severe SA, whether central or obstructive in origin.
Purpose
In the present analysis we studied in patients with heart failure the contribution of obesity in the relationship between SA, measured by RDI, and AF.
Methods
Patients with ejection fraction ≤35% implanted with an ICD endowed with an algorithm (ApneaScan) that calculates the RDI each night, were enrolled and followed-up for 24 months. The weekly mean RDI value was considered, as calculated during the entire follow-up period. The endpoint was daily AF burden of ≥6 hours.
Results
164 patients (age 67±10 years, 75% male, ejection fraction 29±5%) had usable RDI values during the entire follow-up period. Body mass index (BMI) was <25 kg/m2 in 62 patients (normal), 25.0–29.9 kg/m2 in 66 patients (overweight), ≥ 30 kg/m2 in 36 patients (obese). When compared with normal patients (31±11 episodes/h), the average RDI value calculated during the entire follow-up period did not differ in overweight patients (35±13 episodes/h, p=0.114), but was significantly higher in obese patients (39±12 episodes/h, p=0.002). During follow-up, AF burden ≥6 hours/day was documented in 48 (29%) patients (BMI ≥ versus <25 kg/m2; HR: 1.47, 95% CI: 0.83–2.60, p=0.197; BMI ≥ versus <30 kg/m2; HR: 0.98, 95% CI: 0.46–2.09, p=0.963). Based on the ROC curve analysis, average RDI ≥37 episodes/h maximized sensitivity and specificity for the prediction of AF (Area under the curve: 0.63, 95% CI: 0.55–0.70, p=0.011). Device-detected RDI ≥37 episodes/h was associated with the occurrence of AF on univariate analysis (HR: 3.88, 95% CI: 2.02–7.44, p<0.001), as well as after correction for either BMI ≥25 kg/m2 (HR: 3.76, 95% CI: 1.94–7.26, p<0.001), or BMI ≥30 kg/m2 (HR: 4.15, 95% CI: 2.15–8.04, p<0.001).
Conclusions
In heart failure patients, we confirmed the association between ICD-detected SA and AF, an association that persisted independent of patient body habitus.
Funding Acknowledgement
Type of funding sources: Private grant(s) and/or Sponsorship. Main funding source(s): The study is supported by a research grant from Boston Scientific
Collapse
Affiliation(s)
- G Boriani
- Modena Polyclinic Modena University Hospital , Modena , Italy
| | - I Diemberger
- Institute of Cardiology, Univ. of Bologna , Bologna , Italy
| | | | | | | | - A Capucci
- Marche Polytechnic University of Ancona , Ancona , Italy
| | | | - M Zecchin
- University of Trieste , Trieste , Italy
| | | | - M Piacenti
- Fondazione Toscana Gabriele Monasterio , Pisa , Italy
| | - C Indolfi
- Magna Graecia University of Catanzaro , Catanzaro , Italy
| | - M A Arias
- Hospital Virgen de la Salud , Toledo , Spain
| | - C Checchinato
- Santa Croce Hospital of Moncalieri , Moncalieri , Italy
| | - A D'Onofrio
- AO dei Colli - Monaldi Hospital , Naples , Italy
| |
Collapse
|
5
|
Proietti M, Romiti GF, Vitolo M, Harrison SL, Lane DA, Fauchier L, Marin F, Näbauer M, Potpara TS, Dan GA, Maggioni AP, Cesari M, Boriani G, Lip GYH, Ekmekçiu U, Paparisto V, Tase M, Gjergo H, Dragoti J, Goda A, Ciutea M, Ahadi N, el Husseini Z, Raepers M, Leroy J, Haushan P, Jourdan A, Lepiece C, Desteghe L, Vijgen J, Koopman P, Van Genechten G, Heidbuchel H, Boussy T, De Coninck M, Van Eeckhoutte H, Bouckaert N, Friart A, Boreux J, Arend C, Evrard P, Stefan L, Hoffer E, Herzet J, Massoz M, Celentano C, Sprynger M, Pierard L, Melon P, Van Hauwaert B, Kuppens C, Faes D, Van Lier D, Van Dorpe A, Gerardy A, Deceuninck O, Xhaet O, Dormal F, Ballant E, Blommaert D, Yakova D, Hristov M, Yncheva T, Stancheva N, Tisheva S, Tokmakova M, Nikolov F, Gencheva D, Shalganov T, Kunev B, Stoyanov M, Marchov D, Gelev V, Traykov V, Kisheva A, Tsvyatkov H, Shtereva R, Bakalska-Georgieva S, Slavcheva S, Yotov Y, Kubíčková M, Marni Joensen A, Gammelmark A, Hvilsted Rasmussen L, Dinesen P, Riahi S, Krogh Venø S, Sorensen B, Korsgaard A, Andersen K, Fragtrup Hellum C, Svenningsen A, Nyvad O, Wiggers P, May O, Aarup A, Graversen B, Jensen L, Andersen M, Svejgaard M, Vester S, Hansen S, Lynggaard V, Ciudad M, Vettus R, Muda P, Maestre A, Castaño S, Cheggour S, Poulard J, Mouquet V, Leparrée S, Bouet J, Taieb J, Doucy A, Duquenne H, Furber A, Dupuis J, Rautureau J, Font M, Damiano P, Lacrimini M, Abalea J, Boismal S, Menez T, Mansourati J, Range G, Gorka H, Laure C, Vassalière C, Elbaz N, Lellouche N, Djouadi K, Roubille F, Dietz D, Davy J, Granier M, Winum P, Leperchois-Jacquey C, Kassim H, Marijon E, Le Heuzey J, Fedida J, Maupain C, Himbert C, Gandjbakhch E, Hidden-Lucet F, Duthoit G, Badenco N, Chastre T, Waintraub X, Oudihat M, Lacoste J, Stephan C, Bader H, Delarche N, Giry L, Arnaud D, Lopez C, Boury F, Brunello I, Lefèvre M, Mingam R, Haissaguerre M, Le Bidan M, Pavin D, Le Moal V, Leclercq C, Piot O, Beitar T, Martel I, Schmid A, Sadki N, Romeyer-Bouchard C, Da Costa A, Arnault I, Boyer M, Piat C, Fauchier L, Lozance N, Nastevska S, Doneva A, Fortomaroska Milevska B, Sheshoski B, Petroska K, Taneska N, Bakrecheski N, Lazarovska K, Jovevska S, Ristovski V, Antovski A, Lazarova E, Kotlar I, Taleski J, Poposka L, Kedev S, Zlatanovik N, Jordanova S, Bajraktarova Proseva T, Doncovska S, Maisuradze D, Esakia A, Sagirashvili E, Lartsuliani K, Natelashvili N, Gumberidze N, Gvenetadze R, Etsadashvili K, Gotonelia N, Kuridze N, Papiashvili G, Menabde I, Glöggler S, Napp A, Lebherz C, Romero H, Schmitz K, Berger M, Zink M, Köster S, Sachse J, Vonderhagen E, Soiron G, Mischke K, Reith R, Schneider M, Rieker W, Boscher D, Taschareck A, Beer A, Oster D, Ritter O, Adamczewski J, Walter S, Frommhold A, Luckner E, Richter J, Schellner M, Landgraf S, Bartholome S, Naumann R, Schoeler J, Westermeier D, William F, Wilhelm K, Maerkl M, Oekinghaus R, Denart M, Kriete M, Tebbe U, Scheibner T, Gruber M, Gerlach A, Beckendorf C, Anneken L, Arnold M, Lengerer S, Bal Z, Uecker C, Förtsch H, Fechner S, Mages V, Martens E, Methe H, Schmidt T, Schaeffer B, Hoffmann B, Moser J, Heitmann K, Willems S, Willems S, Klaus C, Lange I, Durak M, Esen E, Mibach F, Mibach H, Utech A, Gabelmann M, Stumm R, Ländle V, Gartner C, Goerg C, Kaul N, Messer S, Burkhardt D, Sander C, Orthen R, Kaes S, Baumer A, Dodos F, Barth A, Schaeffer G, Gaertner J, Winkler J, Fahrig A, Aring J, Wenzel I, Steiner S, Kliesch A, Kratz E, Winter K, Schneider P, Haag A, Mutscher I, Bosch R, Taggeselle J, Meixner S, Schnabel A, Shamalla A, Hötz H, Korinth A, Rheinert C, Mehltretter G, Schön B, Schön N, Starflinger A, Englmann E, Baytok G, Laschinger T, Ritscher G, Gerth A, Dechering D, Eckardt L, Kuhlmann M, Proskynitopoulos N, Brunn J, Foth K, Axthelm C, Hohensee H, Eberhard K, Turbanisch S, Hassler N, Koestler A, Stenzel G, Kschiwan D, Schwefer M, Neiner S, Hettwer S, Haeussler-Schuchardt M, Degenhardt R, Sennhenn S, Steiner S, Brendel M, Stoehr A, Widjaja W, Loehndorf S, Logemann A, Hoskamp J, Grundt J, Block M, Ulrych R, Reithmeier A, Panagopoulos V, Martignani C, Bernucci D, Fantecchi E, Diemberger I, Ziacchi M, Biffi M, Cimaglia P, Frisoni J, Boriani G, Giannini I, Boni S, Fumagalli S, Pupo S, Di Chiara A, Mirone P, Fantecchi E, Boriani G, Pesce F, Zoccali C, Malavasi VL, Mussagaliyeva A, Ahyt B, Salihova Z, Koshum-Bayeva K, Kerimkulova A, Bairamukova A, Mirrakhimov E, Lurina B, Zuzans R, Jegere S, Mintale I, Kupics K, Jubele K, Erglis A, Kalejs O, Vanhear K, Burg M, Cachia M, Abela E, Warwicker S, Tabone T, Xuereb R, Asanovic D, Drakalovic D, Vukmirovic M, Pavlovic N, Music L, Bulatovic N, Boskovic A, Uiterwaal H, Bijsterveld N, De Groot J, Neefs J, van den Berg N, Piersma F, Wilde A, Hagens V, Van Es J, Van Opstal J, Van Rennes B, Verheij H, Breukers W, Tjeerdsma G, Nijmeijer R, Wegink D, Binnema R, Said S, Erküner Ö, Philippens S, van Doorn W, Crijns H, Szili-Torok T, Bhagwandien R, Janse P, Muskens A, van Eck M, Gevers R, van der Ven N, Duygun A, Rahel B, Meeder J, Vold A, Holst Hansen C, Engset I, Atar D, Dyduch-Fejklowicz B, Koba E, Cichocka M, Sokal A, Kubicius A, Pruchniewicz E, Kowalik-Sztylc A, Czapla W, Mróz I, Kozlowski M, Pawlowski T, Tendera M, Winiarska-Filipek A, Fidyk A, Slowikowski A, Haberka M, Lachor-Broda M, Biedron M, Gasior Z, Kołodziej M, Janion M, Gorczyca-Michta I, Wozakowska-Kaplon B, Stasiak M, Jakubowski P, Ciurus T, Drozdz J, Simiera M, Zajac P, Wcislo T, Zycinski P, Kasprzak J, Olejnik A, Harc-Dyl E, Miarka J, Pasieka M, Ziemińska-Łuć M, Bujak W, Śliwiński A, Grech A, Morka J, Petrykowska K, Prasał M, Hordyński G, Feusette P, Lipski P, Wester A, Streb W, Romanek J, Woźniak P, Chlebuś M, Szafarz P, Stanik W, Zakrzewski M, Kaźmierczak J, Przybylska A, Skorek E, Błaszczyk H, Stępień M, Szabowski S, Krysiak W, Szymańska M, Karasiński J, Blicharz J, Skura M, Hałas K, Michalczyk L, Orski Z, Krzyżanowski K, Skrobowski A, Zieliński L, Tomaszewska-Kiecana M, Dłużniewski M, Kiliszek M, Peller M, Budnik M, Balsam P, Opolski G, Tymińska A, Ozierański K, Wancerz A, Borowiec A, Majos E, Dabrowski R, Szwed H, Musialik-Lydka A, Leopold-Jadczyk A, Jedrzejczyk-Patej E, Koziel M, Lenarczyk R, Mazurek M, Kalarus Z, Krzemien-Wolska K, Starosta P, Nowalany-Kozielska E, Orzechowska A, Szpot M, Staszel M, Almeida S, Pereira H, Brandão Alves L, Miranda R, Ribeiro L, Costa F, Morgado F, Carmo P, Galvao Santos P, Bernardo R, Adragão P, Ferreira da Silva G, Peres M, Alves M, Leal M, Cordeiro A, Magalhães P, Fontes P, Leão S, Delgado A, Costa A, Marmelo B, Rodrigues B, Moreira D, Santos J, Santos L, Terchet A, Darabantiu D, Mercea S, Turcin Halka V, Pop Moldovan A, Gabor A, Doka B, Catanescu G, Rus H, Oboroceanu L, Bobescu E, Popescu R, Dan A, Buzea A, Daha I, Dan G, Neuhoff I, Baluta M, Ploesteanu R, Dumitrache N, Vintila M, Daraban A, Japie C, Badila E, Tewelde H, Hostiuc M, Frunza S, Tintea E, Bartos D, Ciobanu A, Popescu I, Toma N, Gherghinescu C, Cretu D, Patrascu N, Stoicescu C, Udroiu C, Bicescu G, Vintila V, Vinereanu D, Cinteza M, Rimbas R, Grecu M, Cozma A, Boros F, Ille M, Tica O, Tor R, Corina A, Jeewooth A, Maria B, Georgiana C, Natalia C, Alin D, Dinu-Andrei D, Livia M, Daniela R, Larisa R, Umaar S, Tamara T, Ioachim Popescu M, Nistor D, Sus I, Coborosanu O, Alina-Ramona N, Dan R, Petrescu L, Ionescu G, Popescu I, Vacarescu C, Goanta E, Mangea M, Ionac A, Mornos C, Cozma D, Pescariu S, Solodovnicova E, Soldatova I, Shutova J, Tjuleneva L, Zubova T, Uskov V, Obukhov D, Rusanova G, Soldatova I, Isakova N, Odinsova S, Arhipova T, Kazakevich E, Serdechnaya E, Zavyalova O, Novikova T, Riabaia I, Zhigalov S, Drozdova E, Luchkina I, Monogarova Y, Hegya D, Rodionova L, Rodionova L, Nevzorova V, Soldatova I, Lusanova O, Arandjelovic A, Toncev D, Milanov M, Sekularac N, Zdravkovic M, Hinic S, Dimkovic S, Acimovic T, Saric J, Polovina M, Potpara T, Vujisic-Tesic B, Nedeljkovic M, Zlatar M, Asanin M, Vasic V, Popovic Z, Djikic D, Sipic M, Peric V, Dejanovic B, Milosevic N, Stevanovic A, Andric A, Pencic B, Pavlovic-Kleut M, Celic V, Pavlovic M, Petrovic M, Vuleta M, Petrovic N, Simovic S, Savovic Z, Milanov S, Davidovic G, Iric-Cupic V, Simonovic D, Stojanovic M, Stojanovic S, Mitic V, Ilic V, Petrovic D, Deljanin Ilic M, Ilic S, Stoickov V, Markovic S, Kovacevic S, García Fernandez A, Perez Cabeza A, Anguita M, Tercedor Sanchez L, Mau E, Loayssa J, Ayarra M, Carpintero M, Roldán Rabadan I, Leal M, Gil Ortega M, Tello Montoliu A, Orenes Piñero E, Manzano Fernández S, Marín F, Romero Aniorte A, Veliz Martínez A, Quintana Giner M, Ballesteros G, Palacio M, Alcalde O, García-Bolao I, Bertomeu Gonzalez V, Otero-Raviña F, García Seara J, Gonzalez Juanatey J, Dayal N, Maziarski P, Gentil-Baron P, Shah D, Koç M, Onrat E, Dural IE, Yilmaz K, Özin B, Tan Kurklu S, Atmaca Y, Canpolat U, Tokgozoglu L, Dolu AK, Demirtas B, Sahin D, Ozcan Celebi O, Diker E, Gagirci G, Turk UO, Ari H, Polat N, Toprak N, Sucu M, Akin Serdar O, Taha Alper A, Kepez A, Yuksel Y, Uzunselvi A, Yuksel S, Sahin M, Kayapinar O, Ozcan T, Kaya H, Yilmaz MB, Kutlu M, Demir M, Gibbs C, Kaminskiene S, Bryce M, Skinner A, Belcher G, Hunt J, Stancombe L, Holbrook B, Peters C, Tettersell S, Shantsila A, Lane D, Senoo K, Proietti M, Russell K, Domingos P, Hussain S, Partridge J, Haynes R, Bahadur S, Brown R, McMahon S, Y H Lip G, McDonald J, Balachandran K, Singh R, Garg S, Desai H, Davies K, Goddard W, Galasko G, Rahman I, Chua Y, Payne O, Preston S, Brennan O, Pedley L, Whiteside C, Dickinson C, Brown J, Jones K, Benham L, Brady R, Buchanan L, Ashton A, Crowther H, Fairlamb H, Thornthwaite S, Relph C, McSkeane A, Poultney U, Kelsall N, Rice P, Wilson T, Wrigley M, Kaba R, Patel T, Young E, Law J, Runnett C, Thomas H, McKie H, Fuller J, Pick S, Sharp A, Hunt A, Thorpe K, Hardman C, Cusack E, Adams L, Hough M, Keenan S, Bowring A, Watts J, Zaman J, Goffin K, Nutt H, Beerachee Y, Featherstone J, Mills C, Pearson J, Stephenson L, Grant S, Wilson A, Hawksworth C, Alam I, Robinson M, Ryan S, Egdell R, Gibson E, Holland M, Leonard D, Mishra B, Ahmad S, Randall H, Hill J, Reid L, George M, McKinley S, Brockway L, Milligan W, Sobolewska J, Muir J, Tuckis L, Winstanley L, Jacob P, Kaye S, Morby L, Jan A, Sewell T, Boos C, Wadams B, Cope C, Jefferey P, Andrews N, Getty A, Suttling A, Turner C, Hudson K, Austin R, Howe S, Iqbal R, Gandhi N, Brophy K, Mirza P, Willard E, Collins S, Ndlovu N, Subkovas E, Karthikeyan V, Waggett L, Wood A, Bolger A, Stockport J, Evans L, Harman E, Starling J, Williams L, Saul V, Sinha M, Bell L, Tudgay S, Kemp S, Brown J, Frost L, Ingram T, Loughlin A, Adams C, Adams M, Hurford F, Owen C, Miller C, Donaldson D, Tivenan H, Button H, Nasser A, Jhagra O, Stidolph B, Brown C, Livingstone C, Duffy M, Madgwick P, Roberts P, Greenwood E, Fletcher L, Beveridge M, Earles S, McKenzie D, Beacock D, Dayer M, Seddon M, Greenwell D, Luxton F, Venn F, Mills H, Rewbury J, James K, Roberts K, Tonks L, Felmeden D, Taggu W, Summerhayes A, Hughes D, Sutton J, Felmeden L, Khan M, Walker E, Norris L, O’Donohoe L, Mozid A, Dymond H, Lloyd-Jones H, Saunders G, Simmons D, Coles D, Cotterill D, Beech S, Kidd S, Wrigley B, Petkar S, Smallwood A, Jones R, Radford E, Milgate S, Metherell S, Cottam V, Buckley C, Broadley A, Wood D, Allison J, Rennie K, Balian L, Howard L, Pippard L, Board S, Pitt-Kerby T. Epidemiology and impact of frailty in patients with atrial fibrillation in Europe. Age Ageing 2022; 51:6670566. [PMID: 35997262 DOI: 10.1093/ageing/afac192] [Citation(s) in RCA: 24] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2022] [Revised: 06/08/2022] [Indexed: 12/03/2022] Open
Abstract
BACKGROUND Frailty is a medical syndrome characterised by reduced physiological reserve and increased vulnerability to stressors. Data regarding the relationship between frailty and atrial fibrillation (AF) are still inconsistent. OBJECTIVES We aim to perform a comprehensive evaluation of frailty in a large European cohort of AF patients. METHODS A 40-item frailty index (FI) was built according to the accumulation of deficits model in the AF patients enrolled in the ESC-EHRA EORP-AF General Long-Term Registry. Association of baseline characteristics, clinical management, quality of life, healthcare resources use and risk of outcomes with frailty was examined. RESULTS Among 10,177 patients [mean age (standard deviation) 69.0 (11.4) years, 4,103 (40.3%) females], 6,066 (59.6%) were pre-frail and 2,172 (21.3%) were frail, whereas only 1,939 (19.1%) were considered robust. Baseline thromboembolic and bleeding risks were independently associated with increasing FI. Frail patients with AF were less likely to be treated with oral anticoagulants (OACs) (odds ratio 0.70, 95% confidence interval 0.55-0.89), especially with non-vitamin K antagonist OACs and managed with a rhythm control strategy, compared with robust patients. Increasing frailty was associated with a higher risk for all outcomes examined, with a non-linear exponential relationship. The use of OAC was associated with a lower risk of outcomes, except in patients with very/extremely high frailty. CONCLUSIONS In this large cohort of AF patients, there was a high burden of frailty, influencing clinical management and risk of adverse outcomes. The clinical benefit of OAC is maintained in patients with high frailty, but not in very high/extremely frail ones.
Collapse
Affiliation(s)
- Marco Proietti
- Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK.,Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.,Geriatric Unit, IRCCS Istituti Clinici Scientifici Maugeri, Milan, Italy
| | - Giulio Francesco Romiti
- Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK.,Department of Translational and Precision Medicine, Sapienza - University of Rome, Italy
| | - Marco Vitolo
- Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK.,Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy.,Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy
| | - Stephanie L Harrison
- Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK
| | - Deirdre A Lane
- Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK.,Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
| | - Laurent Fauchier
- Service de Cardiologie, Centre Hospitalier Universitaire Trousseau, Tours, France
| | - Francisco Marin
- Department of Cardiology, Hospital Universitario Virgen de la Arrixaca, IMIB-Arrixaca, University of Murcia, CIBER-CV, Murcia, Spain
| | - Michael Näbauer
- Department of Cardiology, Ludwig-Maximilians-University, Munich, Germany
| | - Tatjana S Potpara
- School of Medicine, University of Belgrade, Belgrade, Serbia.,Clinical Center of Serbia, Belgrade, Serbia
| | - Gheorghe-Andrei Dan
- University of Medicine, 'Carol Davila', Colentina University Hospital, Bucharest, Romania
| | - Aldo P Maggioni
- ANMCO Research Center, Heart Care Foundation, Florence, Italy
| | - Matteo Cesari
- Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.,Geriatric Unit, IRCCS Istituti Clinici Scientifici Maugeri, Milan, Italy
| | - Giuseppe Boriani
- Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy
| | - Gregory Y H Lip
- Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK.,Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Pascale R, Abdullah TA, Fabbricatore D, De Potter T, Ripa M, Durante-Mangoni E, Leventopulos G, Domenichini G, Iacopino S, Akova M, Diemberger I, Viale P, Giannella M. Risk factors for gram-negative infection of cardiovascular implantable electronic devices: retrospective multicenter study - CarDINe study. Europace 2022. [DOI: 10.1093/europace/euac053.541] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: Public Institution(s). Main funding source(s): Dr. Fabbricatore is supported by a research grant from the CardioPaTh PhD Program
Background
Gram-negative bacteria (GNB) are unfrequently isolated from patients with cardiac implantable electronic device (CIED) infection. However, data about risk factors for GNB-CIED-infection and associated clinical outcome are missing.
Methods
Multicenter, retrospective case-control-control study. Adult patients undergoing CIED implantation from Jan 2015 to Dec 2019 were included and classified as case (C) if diagnosed of GNB-CIED-infection; control 1 (C1) if diagnosed with Gram positive bacteria (GPB)-CIED infection; and control 2 (C2) if no CIED-infection was diagnosed during the study period. Patients were matched by center and risk period (from CIED implantation to infection diagnosis ±1 month), with a minimum follow-up period after infection diagnosis of 180 days.
Results
Study cohort consisted of 134 patients (33 C, 53 C1 and 42 C2) from 11 centers. Overall, 99 (73.9%) were male, median age 73 (IQR 66-81) years. Cardiac diseases leading to CIED implantation were bradi-arrythmia (48%), hearth failure (23.5), and primary prevention (20.6%). There were not differences for demographic variables and Charlson Index between C, C1 and C2. Time from implantation to infection diagnosis was similar between C and C1 [274 (39-621) vs 220 (58-866) days, p=0.581]. Shariff score was lower in C compared with C1 [1(1-2) vs 2 (1-3); p<0.001]. C reported more frequently than C1 a prior infection (not CIED related) (33% vs 16%, p=0.08). GN and GP causative agents of CIED-infection are depicted in Fig.1. No differences regarding CIED-infection type (pocket site, endocarditis) were observed between C and C1. Interestingly, PET-FDG was more frequently performed in C compared with C1 (41.2% vs 17%, p=0.013), with a trend toward higher yielding (83% vs. 50%, p=0.16). CIED extraction was performed in 79.4% and 92.5% (p=0.07) of C and C1, respectively. Length of stay was similar between groups [17 (7-39) vs23 (12-41) days, p=0.326]. 6-month survival was significantly lower in C compared with C1 and C2 at Kaplan Meier analysis (Fig.2).
Conclusions
GNB-CIED infection is associated with higher 6-month mortality than GPB- or no-CIED infections, prior GNB infection may favor subsequent GNB-CIED infection, the role of PET-FDG in diagnosing GNB-CIED infection seems to be key.
Collapse
Affiliation(s)
- R Pascale
- University of Bologna - Alma Mater Studiorum, Infectious disease, Bologna, Italy
| | - TA Abdullah
- Hacettepe University, Infectious disease, Ankara, Turkey
| | - D Fabbricatore
- Cardiovascular Research Center OLVZ - Aalst, Aalst, Belgium
| | - T De Potter
- Cardiovascular Research Center OLVZ - Aalst, Aalst, Belgium
| | - M Ripa
- University Vita-Salute San Raffaele, Milan, Italy
| | | | | | - G Domenichini
- University Hospital of Lausanne, Lausanne, Switzerland
| | - S Iacopino
- Maria Cecilia Hospital, Cotignola, Italy
| | - M Akova
- Hacettepe University, Infectious disease, Ankara, Turkey
| | - I Diemberger
- Institute of Cardiology University of Bologna, Bologna, Italy
| | - P Viale
- University of Bologna - Alma Mater Studiorum, Infectious disease, Bologna, Italy
| | - M Giannella
- University of Bologna - Alma Mater Studiorum, Infectious disease, Bologna, Italy
| |
Collapse
|
7
|
Martignani C, Ziacchi M, Statuto G, Spadotto A, Angeletti A, Massaro G, Bartoli L, Orlandi M, Diemberger I, Ginex S, Provasi F, Grassini D, Galie N, Biffi M. Rapid mode in novel generation visually guided laser balloon system: feasibility, safety, and impact on procedural outcomes. Europace 2022. [DOI: 10.1093/europace/euac053.095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Background
Laser balloon (LB) systems are increasingly used for pulmonary vein isolation (PVI) in catheter ablation of atrial fibrillation (AF). The novel generation of the visually guided LB system includes a rapid mode (RM) feature, which potentially allows a continuous circumferential lesion for PVI. Nevertheless, data on its practicability and on its impact on procedural outcomes are lacking.
Purpose
To analyse the applicability of RM and its effect on procedural and fluoroscopic time in a cohort of patients who underwent catheter ablation of AF using a LB system.
Methods
Between September 2020 and December 2021, we prospectively included all consecutive patients who underwent PVI with LB at our centre. All the procedures were performed by the same two operators. For each pulmonary vein (PV), we firstly attempted to obtain a complete circumferential lesion at 13 W using the RM. If its application was not possible or incomplete, we performed additional single lesions at 5.5, 8.5 or 13 W to achieve complete visual PVI. Finally, we calculated the percentage of singular and total circumferential lesions made with RM for every procedure and evaluated its influence on procedural outcomes.
Results
75 patients were enrolled. We identified and successfully isolated 289 PVs, with mean procedural and fluoroscopic time of 171±51 and 38±15 min, respectively. Use of RM for more than 70% of the circumferential lesion was possible in 185 veins (64%), while we obtained complete isolation using only RM in 90 veins (31%). Reasons for interruption of RM were unfavourable anatomy, imperfect visualization of the ostium of the PV and presence of blood between the balloon and the anatomic substrate. For each vein, we observed a significantly shorter ablation (13±8 vs 23±12 min, p<0.001) and fluoroscopic time (3±3 vs 5±4 min, p<0.01) if >70% of the circumferential lesion was made through RM. Further, total procedural (157 ±52 vs 192±42 min, p<0.01), ablation (53±17 vs 88±27, p >0.001) and fluoroscopic time (30±15 vs 36.9±14 min, p 0.025) were significantly shorter if more than 70% of total circumferential lesion was achieved through rapid mode. There were five pinhole balloon ruptures during application of RM. No major complication occurred.
Conclusions
RM is a novel feature in the latest generation of LB system. In our cohort, it showed good applicability and safety, while significantly reducing procedural times. Further studies are needed to understand its possible impact on clinical outcomes.
Collapse
Affiliation(s)
- C Martignani
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - M Ziacchi
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - G Statuto
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - A Spadotto
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - A Angeletti
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - G Massaro
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - L Bartoli
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - M Orlandi
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - I Diemberger
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - S Ginex
- Biotronik Italia spa, Milano, Italy
| | | | | | - N Galie
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - M Biffi
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| |
Collapse
|
8
|
Spadotto A, Toniolo S, Bartoli L, Statuto G, Angeletti A, Massaro G, Martignani C, Ziacchi M, Diemberger I, Galie N, Biffi M. Implantable cardioverter defibrillator in arrhythmogenic cardiomyopathy: which role for antitachycardia pacing? Europace 2022. [DOI: 10.1093/europace/euac053.387] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Background
Arrhythmogenic Cardiomyopathy (ACM) is an inherited cardiomyopathy characterized by ventricular arrhythmias and sudden cardiac death. Implantable cardioverter defibrillator (ICD) remains the only proven therapy to reduce mortality in ACM.
Purpose
The objective of this study was to identify characteristics of ventricular arrhythmias and treatment in patients with ACM.
Method
Retrospective analysis of the data of consecutives patients with confirmed diagnosis of ACM based on the proposed Padua Criteria, who underwent implantation of transvenous ICD from January 1992 and October 2021. The clinical data and information about appropriate and inappropriate ICD therapies were obtained from medical records with the review of the available intra-cardiac electrograms (EGMs).
Results
We enrolled 52 patients (69% males, mean age at implant 48.9 ±14.8 years), 27 (52%) were implanted for primary prevention, 25 (48%) for secondary prevention. After a median follow-up of 7.52 years [IQR: 4.37 - 12.0], 32 patients (61.5%) had 914 sustained episodes of ventricular arrhythmias (VA). 25 patients (48%) had 309 episodes of life-threatening arrhythmias (LT-VA), defined as sustained ventricular tachycardia ≥200 beats/min. In 29/32 patients (91%) ATP treated at least one episode of VA and in 14/25 (56%) at least one episode of LT-VA. Ventricular tachycardia (VT) detection was programmed at least 20 seconds, while VF detection was at least 7 seconds. Among patients with appropriate ICD activation, the first treated episode was a LT-VA in 50% of cases. Out of 914 VA episodes, 735 (80.4%) were treated with ATP and 179 (19.6%) with shocks. Considering LT-VA (cycle length 248 ± 25 ms), 201/309 (65%) and 108/309 (35%) episodes were treated with ATP and shocks, respectively. In 13 patients (25%) there was an inappropriate ICD activation, mostly caused by atrial fibrillation, while in 8 patients (15%) there was a complication needing reintervention (in 3 cases there was a loss of ventricular sensing dictating lead revision).
Conclusions
ACM patients are at risk of VA and LT-VA. The majority of VA at follow-up are monomorphic at rate <200 beats/minute, however the first treated VA episode is a LT-VA in half of cases. ATP is highly successful in terminating VT and even LT-VA, which questions the use of non-transvenous ICD in this young patient population. Nevertheless, transvenous ICDs are burdened by a relevant rate of lead complications which should be weighed in the choice of the ICD type.
Collapse
Affiliation(s)
- A Spadotto
- S. Orsola-Malpighi Policlinic, Bologna, Italy
| | - S Toniolo
- S. Orsola-Malpighi Policlinic, Bologna, Italy
| | - L Bartoli
- S. Orsola-Malpighi Policlinic, Bologna, Italy
| | - G Statuto
- S. Orsola-Malpighi Policlinic, Bologna, Italy
| | - A Angeletti
- S. Orsola-Malpighi Policlinic, Bologna, Italy
| | - G Massaro
- S. Orsola-Malpighi Policlinic, Bologna, Italy
| | | | - M Ziacchi
- S. Orsola-Malpighi Policlinic, Bologna, Italy
| | | | - N Galie
- S. Orsola-Malpighi Policlinic, Bologna, Italy
| | - M Biffi
- S. Orsola-Malpighi Policlinic, Bologna, Italy
| |
Collapse
|
9
|
Martignani C, Ziacchi M, Statuto G, Spadotto A, Angeletti A, Massaro G, Bartoli L, Cascioli G, Ginex S, Grassini D, Diemberger I, Galie N, Biffi M. Learning curve for laser balloon ablation in the treatment of atrial fibrillation: a single center experience. Europace 2022. [DOI: 10.1093/europace/euac053.094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Background
Visually guided laser balloon ablation (LBA) is a promising method for pulmonary vein (PV) isolation in the treatment of atrial fibrillation (AF). To reduce procedural times, the rapid mode feature (RM), which offers an automated continuous 360° lesion for pulmonary vein isolation, was implemented in the latest version of the laser balloon system.
Purpose
We evaluated the learning curve for LBA in the treatment of AF
Method
We enrolled the first 74 patients with paroxysmal or persistent AF treated with LBA in our centre between September 2020 and December 2021. Exclusion criteria were any contraindication for the procedure. 3 different time intervals were considered (time 1 T1, time 2 T2 and time 3 T3), which included the first 25 patients, the next 25 patients and the last 24 patients, respectively. We compared fluoroscopy and procedural time and the number of pulmonary veins isolated by RM >90% (>324°) among the three group were compared.
Results
There was no difference between the three intervals in terms of age (61.2 ±9.00 vs 63.9 ±11.4 vs 58.4 ±12.9; p=n.s.), sex (68% vs 64% vs 81%; p=n.s.) and clinical characteristics. The procedural time (see picture 1) was significantly reduced from T1 to T2 (199 ±51.8 in T1 vs 159 ±38.6 in T2; p< 0.01), while there was no variation between T2 and T3 (159 ±38.6 in T2 vs 153 ±51.9 in T3; p=n.s.). We detected a reduction in fluoroscopy time between T1 and T2 (38.8 ±15.2 in T1 vs 28.8 ±10.5 in T2; p<0.01) but not further reduction was observed between T2 and T3 (28.8 ±10.5 in T2 vs 30.5 ±16.7 in T3; p =n.s.). Considering the use of (RM) feature, there was a progressive increase in the number of PVs isolated by RM >90% over time (1.0 ±0.7 PVs in T1 vs 2.0 ±1.2 PVs in T2 vs 3.3 ±0.9 in T3: p <0.01). Five pinhole balloon ruptures were observed, three in the T1 group, two in the T3 group. Temporary phrenic nerve dysfunction occurred in 1 patient in the T3 interval. No other complications were reported.
Conclusions
PV isolation by visually guided LBA is a safe procedure even during the learning curve. The system is user friendly and procedural time and fluoroscopy time reduced after a limited number of procedures.
Collapse
Affiliation(s)
- C Martignani
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - M Ziacchi
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - G Statuto
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - A Spadotto
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - A Angeletti
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - G Massaro
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - L Bartoli
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - G Cascioli
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - S Ginex
- Biotronik Italia spa, Milano, Italy
| | | | - I Diemberger
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - N Galie
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - M Biffi
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| |
Collapse
|
10
|
Diemberger I, Fumagalli S, Mazzone A, Kirchhof P, De Caterina R. The impact of subjective vs objective frailty on the effectiveness and safety outcomes in patients from ETNA-AF-Europe registry. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.2826] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Since the risk of atrial fibrillation (AF) increases with ageing, frail patients tend to require long-term anticoagulation. Anticoagulated frail patients may be at increased risk of major bleeding, which becomes more frequent in the elderly. Therefore, oral anticoagulation is often withheld or discontinued in frail, older patients with AF.
Purpose
To compare patient characteristics and annualised stroke and bleeding event rates in subjectively and objectively frail patients in the overall population included in the ETNA-AF-Europe registry. The 1-year follow-up was based on a snapshot dated 31st October 2019.
Methods
ETNA-AF-Europe is a multinational, multicentre, post-authorisation, observational study conducted in patients with AF following an edoxaban treatment regimen. Subjective frailty was categorised using a yes/no option, as perceived by physicians as a personal global judgement, without any external interference. Objective frailty was assessed using an adapted Modified Frailty Index; a shortened, simplified version of the Frailty Index.
Results
ETNA-AF Europe compiled data from 13,092 patients treated with edoxaban once daily, 10.6% and 5.0% were classified as subjectively and objectively frail, respectively (Table 1). Patients classified as objectively frail were younger, had a higher body mass index and higher CHA2DS2-VASc and HAS-BLED scores compared with the subjectively frail patients (Table 1), showing minimal overlap between the two groups. Stroke, major bleeding, all-cause and cardiovascular deaths were higher in patients classified as frail (Figure 1). Annualised event rates were mostly comparable in subjectively and objectively frail patients, except for higher annualised rates of ischaemic stroke, observed in subjectively frail patients, and higher annualised rates of myocardial infarction in objectively frail patients (Figure 1). The adherence to drug recommendations was similar in the subjectively and objectively frail cohorts (78.0% and 79.1%, respectively), but lower than in the general AF population (82.9%) (Table 1).
Conclusions
The presence of frailty (either subjective or objective) predicts cardiovascular events in anticoagulated patients with AF. A comprehensive assessment of frailty could improve the routine care of patients with AF.
Funding Acknowledgement
Type of funding sources: Private company. Main funding source(s): Daiichi Sankyo Europe GmbH
Collapse
Affiliation(s)
- I Diemberger
- University of Bologna, Cardiology, Bologna, Italy
| | - S Fumagalli
- University of Florence, Geriatric Intensive Care Unit and Geriatric Arrhythmia Unit, Florence, Italy
| | - A Mazzone
- Fondazione Toscana Gabriele Monasterio, Pisa, Italy
| | - P Kirchhof
- University Heart & Vascular Center Hamburg, Department of Cardiology, Hamburg, Germany
| | - R De Caterina
- University of Pisa, Chair of Cardiology, Pisa, Italy
| | | |
Collapse
|
11
|
Martignani C, Ziacchi M, Statuto G, Bartoli L, Spadotto A, Angeletti A, Massaro G, Diemberger I, Sorrentino S, Capobianco C, Grassini D, Ginex S, Giacopelli D, Galie N, Biffi M. Real use of a novel automatic motorized laser balloon for the ablation of atrial fibrillation. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.0517] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Electric isolation of the pulmonary veins (PVs) can successfully treat patients with atrial fibrillation (AF). Isolation of pulmonary veins can be achieved by several methods: radiofrequency, cryoballoon or laser balloon ablation (LBA). The main procedural challenge with either method is to achieve a continuous circumferential lesion at the left atrium-PVs junction, with the persistence of functional gaps.
Purpose
A novel endoscopic ablation system equipped with a precise motor control system (MCS) has been evaluated. The balloon is used with an endoscope to directly visualize and ablate tissue at the left atrial-PVs junction with laser energy. This system enables uninterrupted, high-speed, circumferential lesion creation under direct control of the physician. The MCS is intended to reduce procedure time and to ensure continuity of ablation lesions. The feasibility of the motorized ablation in terms of extent of applicability along each PV-left atrium junction and time of use of the manual point-by-point mode has been investigated.
Methods
27 consecutive patients (male 70.3%, age 61.2±8.7 years) with paroxysmal or persistent AF who underwent LBA were enrolled in our institution. Exclusion criteria were any contraindication for the procedure including the presence of intracavitary thrombosis and contraindications to general anesthesia or deep sedation. After transseptal puncture, the balloon-based endoscopic ablation system was advanced to each PV ostium, and laser energy were projected onto the target.
Results
A total of 110 PVs were treated with LBA; in 9 patients there was a redundant right intermediate pulmonary vein; in 4 patients there was a right common ostium and in 2 a left common ostium. MCS was used for 82 PVs (74.5%): in particular, MCS was used continuously between 180° and 325° degrees (50 to 90% of PV circumference) for 35 PVs (31.8%) and between 326° and 359° degrees (91 to 99% of PV circumference) for 25 veins (22.7%). In 13 PVs (12%) MCS was used for the entire circumference. During 8508 (19.6%) seconds out of a total of 43.368 seconds, laser energy delivery occurred in the rapid mode by MCS.
No clinical complications, either local or systemic (stroke or TIA, pericardial effusion, pericardial tamponade, pulmonary vein stenosis, esophageal injury, temporary or permanent phrenic nerve palsy), were observed neither during the use of MSC nor during the use of manual point-by-point mode. Of note, a pinhole rupture of the balloon occurred in 3 cases of our series, during the use of MCS, without harm to the patient and requiring only replacement of the LBA.
Conclusions
In our case series, laser balloon ablation with the help of motor control system appears safe and feasible in most cases for large portions of pulmonary vein circumference, providing considerable time sparing (74.5% of total ablation extent in 19.6% of total ablation time).
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- C Martignani
- Sant'Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - M Ziacchi
- Sant'Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - G Statuto
- Sant'Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - L Bartoli
- Sant'Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - A Spadotto
- Sant'Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - A Angeletti
- Sant'Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - G Massaro
- Sant'Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - I Diemberger
- Sant'Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - S Sorrentino
- Sant'Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - C Capobianco
- Sant'Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | | | - S Ginex
- Biotronik Italia spa, Milano, Italy
| | | | - N Galie
- Sant'Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - M Biffi
- Sant'Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| |
Collapse
|
12
|
Boriani G, Pisano' E, Pieragnoli P, Locatelli A, Capucci A, Talarico A, Zecchin M, Rapacciuolo A, Piacenti M, Indolfi C, Arias M, Diemberger I, Checchinato C, D'Onofrio A. Implantable defibrillator-computed respiratory disturbance index predicts new-onset atrial fibrillation: the DASAP-HF study. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.0424] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Introduction
Sleep apnea (SA), as measured by polysomnography, is a risk factor for atrial fibrillation (AF). The DASAP-HF study previously demonstrated that the Respiratory Disturbance Index (RDI) computed by an implantable cardioverter defibrillator (ICD) algorithm accurately identifies severe SA, is associated with cardiovascular events, and independently predicts death.
Purpose
In the present analysis we tested the hypothesis that device-detected RDI could also predict AF burden.
Methods
Patients with left ventricular ejection fraction ≤35% implanted with an ICD were enrolled and followed-up for 24 months. One month after implantation, patients underwent a polysomnographic study. The weekly average RDI value was considered, as calculated by the algorithm during the entire follow-up period and over a 1 week period preceding the sleep study, and patients were stratified according to an RDI value ≥ or <30 episodes/hour. The endpoints were: daily AF burden of ≥5 minutes, ≥6 hours, ≥23 hours.
Results
164 enrolled patients had usable RDI values during the entire follow-up period. Severe SA (RDI≥30 episodes/h) was diagnosed in 92 (56%) patients at the time of the polysomnographic study. During a median follow-up of 25 months, AF burden ≥5 minutes/day was documented in 70 (43%), ≥6 hours/day in 48 (29%), and ≥23 hours/day in 33 (20%) patients. Device-detected RDI≥30 episodes/h at the time of the polysomnographic study, as well as the polysomnography-measured apnea hypopnea index ≥30 episodes/h, were not associated with the occurrence of the endpoints, using a Cox regression model. However, using time-dependent Cox model continuously measured weekly average RDI≥30episodes/h was independently associated with AF burden ≥5 minutes/day (HR: 2.13, 95% CI: 1.24–3.65, p=0.006), ≥6 hours/day (HR: 2.75, 95% CI: 1.37–5.49, p=0.004), and ≥23 hours/day (HR: 2.26, 95% CI: 1.05–4.86, p=0.037), after correction for history of AF, left atrial diameter, and gender.
Conclusions
In heart failure patients implanted with an ICD, device-diagnosed severe SA is associated with a higher risk of AF. In particular, severe SA on follow-up data review identifies patients who are from two- to three-fold more likely to experience an AF episode, according to various thresholds of daily AF burden.
Funding Acknowledgement
Type of funding sources: Private grant(s) and/or Sponsorship. Main funding source(s): Promoted by the Italian Heart Rhythm Society (AIAC).Supported by a research grant from Boston Scientific.
Collapse
Affiliation(s)
- G Boriani
- University of Modena & Reggio Emilia, Modena, Italy
| | | | | | | | - A Capucci
- Marche Polytechnic University of Ancona, Ancona, Italy
| | | | - M Zecchin
- Azienda Sanitaria Universitaria Integrata di Trieste, Trieste, Italy
| | | | - M Piacenti
- Fondazione Toscana Gabriele Monasterio, Pisa, Italy
| | - C Indolfi
- Magna Graecia University of Catanzaro, Catanzaro, Italy
| | - M.A Arias
- Hospital Virgen de la Salud, Toledo, Spain
| | - I Diemberger
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| | - C Checchinato
- Santa Croce Hospital of Moncalieri, Moncalieri, Italy
| | - A D'Onofrio
- AO dei Colli-Monaldi Hospital, Naples, Italy
| | | |
Collapse
|
13
|
Proietti M, Romiti G, Raparelli V, Diemberger I, Boriani G, Marzetti E, Lip G, Cesari M. Prevalence and impact of frailty in patients with atrial fibrillation: a systematic review and meta-analysis. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.0444] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Frailty is a clinical syndrome characterized by a reduced physiologic function, increased vulnerability to stressors, and an increased risk of adverse outcomes. Patients with Atrial Fibrillation (AF) are often burdened with a high number of comorbidities and prone to frailty. The prevalence of frailty, its management and association with major outcomes in patients with AF are still unclear.
Purpose
To estimate the pooled prevalence of frailty in patients with AF, as well as its association with AF-related risk factors and comorbidities, oral anticoagulants (OAC) prescription, and major outcomes.
Methods
We systematically searched PubMed and EMBASE, from inception to 31st January 2021, for studies reporting the prevalence of frailty (irrespective of the tool used for assessment). Pooled prevalence, odds ratio (OR), and 95% Confidence Intervals (CI) were computed using random-effect models; heterogeneity was assessed through the inconsistency index (I2). This study was registered in PROSPERO: CRD42021235854.
Results
A total of 1,116 studies were retrieved from the literature search, and 31 were finally included in the systematic review (n=842,521 patients). The frailty pooled prevalence was 39.6% (95% CI=29.2%-51.0%, I2=100%; Figure 1). Significant subgroup differences were observed according to geographical location (higher prevalence found in European-based cohorts; p=0.003) and type of tool used for the assessment (higher prevalence in studies using the Clinical Frailty Scale and Tilburg Frailty Index tools; p<0.001). Meta-regressions showed that study-level mean age and prevalence of hypertension, diabetes, and history of stroke were directly associated with frailty prevalence. Frailty was significantly associated with a 29% reduced probability of OAC prescription in observational studies (OR=0.71, 95% CI=0.62–0.81). Frail patients with AF were at higher risk of all-cause death (OR=4.12, 95% CI=3.15–5.41), ischemic stroke (OR=1.55, 95% CI=1.01–2.38), and bleeding (OR=1.55, 95% CI=1.12–2.14), compared to non-frail patients with AF.
Conclusions
In this systematic review and meta-analysis analysis, the prevalence of frailty was high in patients with AF, and associated with study-level mean age and prevalence of several stroke risk factors. Frailty may influence the management of patients, and worsening the prognosis for all major AF-related outcomes.
Funding Acknowledgement
Type of funding sources: None. Prevalence of Frailty among AF patients
Collapse
Affiliation(s)
| | - G.F Romiti
- Sapienza University of Rome, Rome, Italy
| | | | | | - G Boriani
- University of Modena & Reggio Emilia, Modena, Italy
| | - E Marzetti
- Catholic University of the Sacred Heart, Rome, Italy
| | - G.Y.H Lip
- University of Liverpool, Liverpool, United Kingdom
| | - M Cesari
- University of Milan, Milan, Italy
| |
Collapse
|
14
|
Martignani C, Ziacchi M, Statuto G, Bartoli L, Spadotto A, Angeletti A, Massaro G, Diemberger I, Sorrentino S, Capobianco C, Giacopelli D, Bassini M, Grassini D, Galie N, Biffi M. Third-generation laser balloon ablation: rapid mode applicability is associated with shorter time to pulmonary vein isolation. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.0516] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
The rapid mode feature implemented in the latest version of the laser balloon system (LB3, HeartLight, X3, Cardiofocus) offers an automated continuous 360° lesion for pulmonary vein isolation (PVI). However, data on its clinical applicability and the potential reduction of procedural times are not yet available.
Purpose
To explore the use of the rapid mode and its association with PV total and fluoroscopy times in our initial experience with LB3.
Methods
This analysis included consecutive patients who underwent PVI procedure with LB3. We attempted to perform a complete circular ablation line using the rapid mode at 13 W, but if needed to achieve successful isolation, rapid mode was interrupted and manual mode (5.5–8.5 W) applications were used. The percentage of rapid mode use on the 360° lesion was measured for each PV. Total and fluoroscopy times to complete PVI were also collected.
Results
A total of 110 PVs were identified in 27 LB3 procedures and successfully isolated with a mean procedural time of 85±31 min. Sixty (55%) PVs were treated by using rapid mode for more than 50% (180°) lesion and 13 (12%) of them had a pure rapid mode ablation (without necessity of manual mode applications). Right inferior PV had the highest use of rapid mode (median value 70%). The main reasons for manual applications were poor PV occlusion, imperfect ostium visualization and presence of blood. PVs with >50% rapid mode use were treated in a significantly shorter time (21.2±13.7 vs 26.8±12.4, p=0.043). Fluoroscopy time did not differ significantly (4.7±4.2 vs 5.4±4.9, p=0.48). Three pinhole balloon ruptures were observed during rapid mode energy application in the second, third and twenty-fifth procedure. No other complications occurred.
Conclusions
Few PVs could be isolated using pure rapid mode; however, its applicability for more than 50% lesion was observed more frequently and significantly reduced the time to isolation.
Funding Acknowledgement
Type of funding sources: None. Time to isolation using Rapid Mode
Collapse
Affiliation(s)
- C Martignani
- Sant'Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - M Ziacchi
- Sant'Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - G Statuto
- Sant'Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - L Bartoli
- Sant'Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - A Spadotto
- Sant'Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - A Angeletti
- Sant'Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - G Massaro
- Sant'Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - I Diemberger
- Sant'Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - S Sorrentino
- Sant'Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - C Capobianco
- Sant'Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | | | | | | | - N Galie
- Sant'Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - M Biffi
- Sant'Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| |
Collapse
|
15
|
Angeletti A, Ziacchi M, Martignani C, Massaro M, Statuto G, Sorrentino S, Piemontese GP, Capobianco C, Spadotto A, Minguzzi A, Diemberger I, Biffi M. Slow VT treatment in a contemporary population of primary prevention ICD recipients. Europace 2021. [DOI: 10.1093/europace/euab116.411] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Background
Implantable cardioverter defibrillator (ICD) is an effective therapy for sudden cardiac death (SCD). 2015 HRS/EHRA/APHRS/SOLAECE expert consensus document suggests long VT detection, above 185 bpm, as optimal ICD programming to reduce unnecessary therapies in primary prevention (PP).
Purpose
The aim of our study is to evaluate incidence, safety and efficacy of ICD treatment for VT arrhythmias below 185 bpm, in a contemporary population of PP ICD recipients with long detection intervals (LDI), morphological discrimination algorithm and antitachycardia pacing therapies (ATP) before shock.
Methods
We conducted a single centre retrospective study enrolling 236 patients implanted with a primary-prevention indication from January 2013 to June 2019. Patients were implanted with single or dual chamber single-lead transvenous ICD. All patients had standard device setting with long (at least 20 s in VT and 7 s in VF) VT/VF detection above 150 bpm and therapies starting from 171 with up to 5 ATP and multiple shocks. PainFREE-like bursts and Schaumann-like ramps ATP were always set in VT zone. Of each patient we collected a detailed report of up to five appropriate events and three inappropriate events. Arrhythmia diagnosis was confirmed from 3 independent expert physicians. Date of the event, cycle length, type of morphology (polymorphic or monomorphic), therapies with their effect were collected.
Results
During a mean follow-up of 42 months, 47 (20 %) and 18 (8%) patients had at least one appropriate and inappropriate activation, respectively. The detailed-events analysis shows that 16 (7%) patients had 38 (30%) appropriate events with rate <188 bpm. At these rate ATP were 97% effective. 14 (38%) of inappropriate activations were caused by arrythmias with ventricular rate below 188 bpm and half of these received a shock; 30% of inappropriate shocks were due to arrhythmia with rate <188 bpm. 73% of treated events, with rate <188 bpm, were appropriate. Only 5.6% (n = 10) of ATP attempts cause arrhythmia acceleration.
Conclusions
One third of detected arrhythmias had a rate below 188 bpm and 73% were true VT. In this slow VT zone, ATP had a high success rate with low percentage of acceleration.
Collapse
Affiliation(s)
- A Angeletti
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| | - M Ziacchi
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| | - C Martignani
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| | - M Massaro
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| | - G Statuto
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| | - S Sorrentino
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| | - GP Piemontese
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| | - C Capobianco
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| | - A Spadotto
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| | - A Minguzzi
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| | - I Diemberger
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| | - M Biffi
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| |
Collapse
|
16
|
Diemberger I, Guerra F, Calo" L, D"onofrio A, Manzo M, Santini L, Giubilato G, Carriere C, Santobuono VE, Savarese G, La Greca C, Arena G, Talarico A, Valsecchi S, Ziacchi M. Implantable cardioverter defibrillator multisensor monitoring during home confinement caused by the covid-19 pandemic. Europace 2021. [PMCID: PMC8194661 DOI: 10.1093/europace/euab116.469] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Funding Acknowledgements Type of funding sources: None. Background Utilization of remote monitoring platforms was recommended amidst the COVID-19 pandemic. The HeartLogic algorithm combines data from multiple implantable cardioverter defibrillator (ICD) sensors (first and third heart sounds, intrathoracic impedance, respirations, night heart rate, and patient activity) to provide integrated data that may allow for detection of early signs of worsening HF. Purpose We examined whether the HeartLogic platform may elucidate behavioral changes that impact HF decompensation, and the possible consequences of home confinement caused by the COVID-19 pandemic. Methods The Italian lockdown was imposed from March 8th to May 18th. On March 8th 2020, the HeartLogic feature was active in 349 ICD and cardiac resynchronization therapy ICD patients at 20 Italian centers. The period from January 1st to July 19th was divided in 3 phases: Pre-Lockdown (weeks 1-11), Lockdown (weeks 12-20), Post-Lockdown (weeks 21-29). Results Immediately after the implementation of stay at home orders (week 12) we observed a significant drop in median activity level (65min [36-103] in week 12 vs. 101min [61-140] in Pre-Lockdown; p < 0.001), while there was no difference in the other contributing sensors. The median composite HeartLogic index increased at the end of Lockdown (4.7 [1.3-10.2] in week 20 vs. 2.5 [0.7-7.0] in Pre-Lockdown; p = 0.019). The weekly rate of HeartLogic alerts was significantly higher during Lockdown (1.56 alerts/week/100pts, 95%CI:1.15-2.06; IRR = 1.71, p = 0.014) and Post-Lockdown (1.37 alerts/week/100pts, 95%CI:0.99-1.84; IRR = 1.50, p = 0.072) than that reported in Pre-Lockdown (0.91 alerts/week/100pts, 95%CI:0.64-1.27). However, the median duration of alert state and the maximum index value did not change among phases, as well as the proportion of alerts followed by clinical actions at the centers (Pre-Lockdown: 31%, Lockdown: 22%, Post-Lockdown: 28%), and the proportion of alerts fully managed remotely (i.e. no in-clinic visits) (Pre-Lockdown: 89%, Lockdown: 90%, Post-Lockdown: 88%). Conclusions The system was sensitive to the behavioral changes occurred during the lockdown, i.e. decrease in activity. However, the home confinement had no impact on the other sensors. The higher rate of HeartLogic alerts during lockdown and the increase in the median index after 8 weeks of home confinement suggest the worsening of the HF status, possibly explained by the behavioral changes. Nonetheless, the management of the HF detected events (actions performed and management strategy) was not impacted by the restrictions.
Collapse
Affiliation(s)
- I Diemberger
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| | - F Guerra
- University Hospital Riuniti of Ancona, Ancona, Italy
| | - L Calo"
- Polyclinic Casilino of Rome, Rome, Italy
| | - A D"onofrio
- Ospedale Monaldi, Departmental Unit of Electrophysiology, Evaluation and Treatment of Arrhythmias, Naples, Italy
| | - M Manzo
- AOU S. Giovanni di Dio e Ruggi d"Aragona, Salerno, Italy
| | | | - G Giubilato
- Hospital Fabrizio Spaziani, Frosinone, Italy
| | - C Carriere
- University Hospital Riuniti, Trieste, Italy
| | | | - G Savarese
- S. Giovanni Battista Hospital, Foligno, Italy
| | - C La Greca
- Poliambulanza Foundation Hospital Institute of Brescia, Brescia, Italy
| | - G Arena
- Ospedale Civile Apuane, Massa, Italy
| | | | | | - M Ziacchi
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| |
Collapse
|
17
|
Martignani C, Ziacchi M, Statuto G, Spadotto A, Angeletti A, Massaro G, Diemberger I, Sorrentino S, Capobianco C, Grassini D, Giacopelli D, Ginex S, Galie N, Biffi M. Real use of a novel automatic motorized laser balloon for the ablation of atrial fibrillation. Europace 2021. [DOI: 10.1093/europace/euab116.220] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Background
Electric isolation of the pulmonary veins (PVs) can successfully treat patients with atrial fibrillation (AF). Isolation of pulmonary veins can be achieved by several methods: radiofrequency, cryoballoon or laser balloon ablation (LBA). The main procedural challenge with either method is to achieve a continuous circumferential lesion at the left atrium-PVs junction, with the persistence of functional gaps.
Purpose
A novel endoscopic ablation system equipped with a precise motor control system (MCS) has been evaluated. The balloon is used with an endoscope to directly visualize and ablate tissue at the left atrial-PVs junction with laser energy. This system enables uninterrupted, high-speed, circumferential lesion creation under direct control of the physician. The MCS is intended to reduce procedure time and to ensure continuity of ablation lesions. The feasibility of the motorized ablation in terms of extent of applicability along each PV-left atrium junction and time of use of the manual point-by-point mode has been investigated.
Methods
sixteen consecutive patients (male 68.7%, age 60.9 ± 7.8 years) with paroxysmal or persistent AF who underwent LBA were enrolled in our institution. Exclusion criteria were any contraindication for the procedure including the presence of intracavitary thrombosis and contraindications to general anesthesia or deep sedation. After transseptal puncture, the balloon-based endoscopic ablation system was advanced to each PV ostium, and laser energy were projected onto the target.
Results
A total of 62 PVs were treated with LBA; in 3 patients there was a redundant right intermediate pulmonary vein; in 4 patients there was a right common ostium and in one a left common ostium. MCS was used for 41 PVs (66.1%): in particular, MCS was used continuously between 180° and 325° degrees (50 to 90% of PV circumference) for 22 PVs (35.5%) and between 326° and 359° degrees (91 to 99% of PV circumference) for 16 veins (25.8%). In 3 PVs (4.8%) MCS was used for the entire circumference. During 5.659 (23.6%) seconds out of a total of 23.986 seconds, laser energy delivery occurred in the rapid mode by MCS.
No clinical complications, either local or systemic (stroke or TIA, pericardial effusion, pericardial tamponade, pulmonary vein stenosis, esophageal injury, temporary or permanent phrenic nerve palsy), were observed neither during the use of MSC nor during the use of manual point-by-point mode. Of note, a pinhole rupture of the balloon occurred in the first 2 cases of our series, during the use of MCS, without harm to the patient and requiring only replacement of the LBA.
Conclusions
In our case series, laser balloon ablation with the help of motor control system appears safe and feasible in most cases for large portions of pulmonary vein circumference, providing considerable time sparing (66.1% of total ablation extent in 23.6% of total ablation time).
Collapse
Affiliation(s)
- C Martignani
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - M Ziacchi
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - G Statuto
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - A Spadotto
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - A Angeletti
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - G Massaro
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - I Diemberger
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - S Sorrentino
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - C Capobianco
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | | | | | - S Ginex
- Biotronik Italia spa, Milano, Italy
| | - N Galie
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - M Biffi
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| |
Collapse
|
18
|
De Bie J, Diemberger I, Mason JW. Comparison of PR, QRS, and QT interval measurements by seven ECG interpretation programs. J Electrocardiol 2020; 63:75-82. [PMID: 33142185 DOI: 10.1016/j.jelectrocard.2020.10.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2020] [Revised: 08/21/2020] [Accepted: 10/13/2020] [Indexed: 10/23/2022]
Abstract
BACKGROUND Electrocardiograph-generated measurements of PR, QRS, and QT intervals are generally thought to be more precise than manual measurements on paper records. However, the performance of different programs has not been well compared. METHODS Routinely obtained digital electrocardiograms (ECGs), including over 500 pediatric ECGs, were used to create over 2000 10 s analog ECGs that were replayed through seven commercially available electrocardiographs. The measurements for PR interval, QRS duration, and QT interval made by each program were extracted and compared against each other (using the median of the programs after correction for program bias) and the population mean values. RESULTS Small but significant systematic biases were seen between programs. The smallest and largest variation from the population mean differed by 4.7 ms for PR intervals, 5.8 ms for QRS duration, and 12.4 ms for QT intervals. In pairwise comparison programs showed similar accuracy for most ECGs, with the average absolute errors at the 75th percentile for PR intervals being 4-6 ms from the median, QRS duration 4-8 ms, and QT interval 6-10 ms. However, substantial differences were present in the numbers and extent of large, clinically significant errors (e.g at the 98th percentile), for which programs differed by a factor of two for absolute errors, as well as differences in the mix of overestimations and underestimations. CONCLUSIONS When reading digital ECGs, users should be aware that small systematic differences exist between programs and that there may be large clinically important errors in difficult cases.
Collapse
Affiliation(s)
- J De Bie
- Mortara Instrument Europe s.r.l., Bologna, Italy.
| | - I Diemberger
- Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy
| | - J W Mason
- Mason Cardiac Safety Consulting, Reno, Nevada, USA
| |
Collapse
|
19
|
Bakhai A, Fumagalli S, Mazzone A, Diemberger I, Kirchhof P, De Caterina R. Still using “aspirin or nothing” for AF patients with frailty? ETNA-AF-Europe shows frailty corresponds to higher mortality but not neurological bleeding with edoxaban anticoagulation in routine care. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.0634] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Clinicians are encouraged to anticoagulate frail and older patients. Both groups were underrepresented in pivotal AF stroke prevention trials. Large, more geographically generalizable data are needed for safety and treatment efficacy in these groups. Aim: ETNA-AF-Europe registry assessed key clinical outcomes and risk scores in frail and older patients compared to their counterparts.
Methods
ETNA-AF-Europe is a large, prospective, post-authorisation, observational study of patients with AF being prescribed edoxaban. The registry captured frailty as a single, mandatory field as perceived by physicians. Baseline characteristics evaluation and 1-year outcomes of patients were extracted by presence of frailty and age (≥ vs. <80 years) using descriptive analyses.
Results
Of, 13,090 enrolled patients, 10.6% were considered frail with coding complete for 12,212 patients. Whilst 27.9% of patients were aged ≥80, of these only 25.3% were frail. Frail patients differed from non-frail and had similar baseline characteristics to those aged ≥80 years. Frail patients were more frequently female, with lower BMI and higher HAS-BLED risk score (Table), and incurred the highest rates of overall and cardiovascular deaths and major bleeding, even more than those aged ≥80 (Figure). Despite this, intracranial haemorrhage (ICH) was surprisingly low and comparable.
Conclusions
In this large, Europe wide group of patients with AF anticoagulated with edoxaban, patients considered frail by physicians are not always older. A clinical frailty perception is associated with a 4-fold higher short-term mortality. Whilst major bleeding is higher in this frail cohort, ICH is comparably low. The HAS-BLED score in frail patients prescribed edoxaban, appears to predict non-neurological bleeding. These data provide confidence for prescribing edoxaban in frail AF patients to prevent stroke.
One-year outcomes
Funding Acknowledgement
Type of funding source: Private company. Main funding source(s): Daiichi Sankyo Europe GmbH, Munich, Germany
Collapse
Affiliation(s)
- A Bakhai
- Barnet General Hospital, London, United Kingdom
| | | | - A Mazzone
- Fondazione Toscana Gabriele Monasterio, Massa, Italy
| | | | - P Kirchhof
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | | |
Collapse
|
20
|
Kennergren C, Poole JE, Wilkoff BL, Mittal S, Corey GR, Mccomb J, Diemberger I, Wright DJ, Philbert BT, Simmers TA, Boersma LVA, Debus B, Krueger J, Vandersteegen K, Tarakji KG. 1261Geographical variations in the incidence of CIED infection and infection prevention strategies: Update from the global WRAP-IT study. Europace 2020. [DOI: 10.1093/europace/euaa162.364] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Funding Acknowledgements
Medtronic, Inc.
Introduction
Cardiac Implantable Electronic Device (CIED) infections lead to significant morbidity, mortality, and use of health care resources. There is variation in infection prevention strategies among centers, and it is not clear whether there is also variation in infection rates across different geographies. Recently, WRAP-IT, the largest global randomized trial to evaluate an infection reduction strategy, randomized 6,983 patients to receive an antibacterial envelope (treatment) vs. no envelope (control). The results demonstrated a significant reduction in major CIED infection with the TYRX antibiotic envelope (12-mo infection rate for envelope vs. control 0.7% and 1.2%, respectively; HR, 0.60; 95% [CI], 0.36 to 0.98; P = 0.04). The purpose of this analysis is to assess geographical variations in patient characteristics, procedural routines, and infection rates.
Methods
The WRAP-IT study enrolled patients undergoing a CIED pocket revision, generator replacement, or system upgrade or an initial implantation of a cardiac resynchronization therapy defibrillator and randomized them to receive the envelope or not, in addition to mandated pre-procedure intravenous antibiotic prophylaxis. To assess geographical variations in infection rates, the control group (per protocol) baseline demographics and procedural characteristics were identified. Major infection was defined as CIED infections resulting in system extraction or revision, long-term antibiotic therapy with infection recurrence, or death.
Results
A total of 3429 control patients were evaluated and followed for a mean of 20.9 ± 8.3 months; 2530 patients from 123 centers in North America, 777 patients from 46 centers in Europe, and 122 patients from 11 centers in Asia/South America. The 24-month Kaplan-Meier major infection rates were 1.2% in North America (30 pts), 2.5% in Europe (16 pts), and 4.3% Asia/South America (5 pts) (see Figure). These geographical variations in the incidence of major CIED infections were significant (overall P = 0.008, univariate). There were differences in baseline patient characteristics, including age, sex, medication use, NYHA Class, and number of previous devices across geographies. Differences also included procedural characteristics, such as device type, use of pocket wash, skin preparation, pre-operative antibiotic drug use, and procedure time.
Conclusion
Major CIED infection rates vary significantly across geographies. The effect of patient demographics and procedural characteristics on these findings will be assessed and presented at EHRA. Insights into geographical variability of CIED infections is important to mitigate infection risk, reduce morbidity and cost.
Abstract Figure. Major CIED Infection Rate by Geography
Collapse
Affiliation(s)
- C Kennergren
- Sahlgrenska University Hospital, Gothemburg, Sweden
| | - J E Poole
- University of Washington Medical Center, Seattle, United States of America
| | - B L Wilkoff
- Cleveland Clinic, Cleveland, United States of America
| | - S Mittal
- The Valley Hospital, Ridgewood, United States of America
| | - G R Corey
- Duke Clinical Research Institute, Durham, United States of America
| | - J Mccomb
- The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom of Great Britain & Northern Ireland
| | | | - D J Wright
- Liverpool Heart and Chest Hospital, Liverpool, United Kingdom of Great Britain & Northern Ireland
| | - B T Philbert
- Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark
| | - T A Simmers
- Catharina Hospital, Eindhoven, Netherlands (The)
| | - L V A Boersma
- St. Antonius Hospital, Nieuwegein, Netherlands & Amsterdam University Medical Center, Amsterdam, Netherlands (The)
| | - B Debus
- Medtronic, Mounds View, United States of America
| | - J Krueger
- Medtronic, Mounds View, United States of America
| | | | - K G Tarakji
- Cleveland Clinic, Cleveland, United States of America
| |
Collapse
|
21
|
Biffi M, Ziacchi M, Martignani C, Lavalle C, Piro A, Diemberger I. P1157Defibrillation threshold with subcutaneous implantable-cardioverter defibrillator implanted using an intermuscular 2-incision approach. Europace 2020. [DOI: 10.1093/europace/euaa162.145] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Funding Acknowledgements
NO FUNDING
OnBehalf
Rhythm Detect Registry
Background
Current subcutaneous implantable cardioverter–defibrillators (S-ICD) deliver 80J, and the conversion test is usually conducted by delivering shock energy of 65 J to ensure a safety defibrillation margin of at least 15 J. However, little is known about the real safety margin in real life clinical practice.
Purpose
To determine the defibrillation threshold (DFT) with S-ICD and to investigate its association with clinical characteristics.
Methods
De novo S-ICD patients were consecutively enrolled and DFT was evaluated using a pre-specified step-up protocol at implantation.
Results
35 patients, BMI 25 ± 4 kg/m2, left ventricular ejection fraction (LVEF) 48 ± 19%, underwent S-ICD implantation. The generator was positioned in an intermuscular pocket and a 2-incision technique was applied in all patients. The mean DFT was 30 ± 10J and the DFT was >30J in 7 (20%) patients. A single patient had a >40J DFT. The time to shock was 11 ± 3 seconds and the shock impedance was 67 ±21 Ohm at the lowest effective energy. The DFT was comparable in patients with LVEF ≤35% (33 ± 15J) versus >35% (29 ± 5J, p = 0.278), and in patients with BMI ≤25 kg/m2 (30 ± 5J) versus >25kg/m2 (31 ± 14J, p = 0.864).
Conclusions
We observed low DFT and low shock impedance in patients who received S-ICD with an intermuscular 2-incision approach. The S-ICD defibrillation success rate at ≤30J was 80%, while 97% of patients were defibrillated at ≤ 40J. We found no difference in DFT according to the LVEF or the BMI.
Collapse
Affiliation(s)
- M Biffi
- Institute of Cardiovascular Diseases of Bologna, Bologna, Italy
| | - M Ziacchi
- Institute of Cardiovascular Diseases of Bologna, Bologna, Italy
| | - C Martignani
- Institute of Cardiovascular Diseases of Bologna, Bologna, Italy
| | - C Lavalle
- Umberto I Polyclinic of Rome, Rome, Italy
| | - A Piro
- Umberto I Polyclinic of Rome, Rome, Italy
| | - I Diemberger
- Institute of Cardiovascular Diseases of Bologna, Bologna, Italy
| |
Collapse
|
22
|
Bianchi V, Diemberger I, Tavoletta V, Perrotta L, Ottaviano L, Migliore F, Francia P, Ammendola E, De Bonis S, Ferrari P, Dello Russo A, Palmisano P, Salzano G, Lovecchio M, Viani S. P521Conversion test during Subcutaneous Implantable Cardioverter-Defibrillator Implantation in clinical practice: in-hospital and mid-term outcome. Europace 2020. [DOI: 10.1093/europace/euaa162.118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Funding Acknowledgements
No funding
OnBehalf
RHYTHM DETECT Registry
Background
With subcutaneous implantable cardioverter–defibrillators (S-ICD), conversion test (CT) is still recommended at implantation. However, prior works found that adherence to this recommendation is declining in clinical practice.
Purpose
To describe current practice regarding CT at S-ICD implantation, and also measure in-hospital outcome of patients who underwent CT and mid-term outcome of patients without CT.
Methods
We analyzed 1652 consecutive patients (49 ± 15 years old, 80% male, 51% with ischemic or non-ischemic dilated cardiomyopathy, 45% with ejection fraction ≤35%) who underwent S-ICD implantation in 60 Italian centers from 2013 to 2019.
Results
CT data were missing in 27 patients. CT was performed in 1300 patients. Successful conversion with ≤65J was obtained in 97.4% of patients. Shock at 80J was not effective in 12 (0.9%) patients. In 10 of these patients the CT was successful after device repositioning, while in 2 patients it was decided to implant a transvenous ICD. Two (0.15%) episodes of electromechanical dissociation (1 fatal) were reported as consequence of CT. CT was not performed in 325 patients (for clinical reasons in 182 patients, for facility preference in 71, ventricular fibrillation not inducible in 72 patients). As compared to the CT group, these patients were older (51 ± 16 vs. 48 ± 15 years; p < 0.01) and had lower ejection fraction (37 ± 16% vs. 46 ± 16%; p < 0.01). 243 non-CT patients had at least 6 months follow-up (median 15 months). In this group, 12 (4.9%) patients had appropriate shocks to treat VT/VF (all successfully terminated with the first shock), and 9 (3.7%) patients had inappropriate shocks.
Conclusions
This analysis showed that CT is frequently omitted in current clinical practice, especially in older patients with worse systolic function. Shocks at CT are very frequently effective and system revision after CT is rarely required. CT is also safe, although serious adverse events cannot be excluded. A strategy that omits CT did not appear to compromise the effectiveness of the S-ICD, but larger populations and longer follow-up are needed to confirm this finding.
Collapse
Affiliation(s)
- V Bianchi
- AO dei Colli-Monaldi Hospital, Naples, Italy
| | - I Diemberger
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| | - V Tavoletta
- AO dei Colli-Monaldi Hospital, Naples, Italy
| | - L Perrotta
- Azienda Ospedaliera Universitaria Careggi, Florence, Italy
| | - L Ottaviano
- Sant"Ambrogio Clinical Institute, Milan, Italy
| | - F Migliore
- Azienda Ospedaliera di Padova, Padova, Italy
| | | | | | - S De Bonis
- P.O. Civile Ferrari, Castrovillari (Cosenza), Italy
| | - P Ferrari
- Ospedale Papa Giovanni XXIII, Bergamo, Italy
| | - A Dello Russo
- Università Politecnica delle Marche, Torrette di Ancona (AN), Italy
| | - P Palmisano
- Cardinale G. Panico Hospital, Tricase, Italy
| | | | | | - S Viani
- Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
| |
Collapse
|
23
|
De Bie J, Martignani C, Massaro G, Diemberger I. Performance of seven ECG interpretation programs in identifying arrhythmia and acute cardiovascular syndrome. J Electrocardiol 2019; 58:143-149. [PMID: 31884310 DOI: 10.1016/j.jelectrocard.2019.11.043] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2019] [Revised: 10/29/2019] [Accepted: 11/18/2019] [Indexed: 10/25/2022]
Abstract
BACKGROUND No direct comparison of current electrocardiogram (ECG) interpretation programs exists. OBJECTIVE Assess the accuracy of ECG interpretation programs in detecting abnormal rhythms and flagging for priority review records with alterations secondary to acute coronary syndrome (ACS). METHODS More than 2,000 digital ECGs from hospitals and databases in Europe, USA, and Australia, were obtained from consecutive adult and pediatric patients and converted to 10 s analog samples that were replayed on seven electrocardiographs and classified by the manufacturers' interpretation programs. We assessed ability to distinguish sinus rhythm from non-sinus rhythm, identify atrial fibrillation/flutter and other abnormal rhythms, and accuracy in flagging results for priority review. If all seven programs' interpretation statements did not agree, cases were reviewed by experienced cardiologists. RESULTS All programs could distinguish well between sinus and non-sinus rhythms and could identify atrial fibrillation/flutter or other abnormal rhythms. However, false-positive rates varied from 2.1% to 5.5% for non-sinus rhythm, from 0.7% to 4.4% for atrial fibrillation/flutter, and from 1.5% to 3.0% for other abnormal rhythms. False-negative rates varied from 12.0% to 7.5%, 9.9% to 2.7%, and 55.9% to 30.5%, respectively. Flagging of ACS varied by a factor of 2.5 between programs. Physicians flagged more ECGs for prompt review, but also showed variance of around a factor of 2. False-negative values differed between programs by a factor of 2 but was high for all (>50%). Agreement between programs and majority reviewer decisions was 46-62%. CONCLUSIONS Automatic interpretations of rhythms and ACS differ between programs. Healthcare institutions should not rely on ECG software "critical result" flags alone to decide the ACS workflow.
Collapse
Affiliation(s)
- J De Bie
- Mortara Instrument Europe s.r.l., Bologna, Italy.
| | - C Martignani
- Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy
| | - G Massaro
- Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy
| | - I Diemberger
- Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy
| |
Collapse
|
24
|
|
25
|
Angeletti A, Paolisso P, Statuto G, Massaro G, Lorenzetti S, Frisoni J, Martignani C, Ziacchi M, Giacopelli D, Grassini D, Diemberger I, Biffi M. P2883VT/VF treatment in a contemporary population of single chamber ICD recipients: ATP efficacVF. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.1191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Aim of the study
to investigate the efficacy of ATP in consecutive, unselected ICD recipients implanted in 2014–2015.
Methods
All patients had a VT zone as 350 ms and a VF zone as 280 ms programmed, with a detection duration >20 seconds and >8 seconds respectively for VT and VF. Anti-tachycardia pacing (ATP) was available before/during charging in the VF zone, while at least 3 attempts with ATP were programmed in the VT zone. ATP efficacy was assed at the first ventricular arrhythmia episode for each patient. Overall ATP efficacy was also calculated on the burden of treated episodes.
Results
A total of 165 patients (median age 63 [48–72] years, male 79%, primary prevention 80%, ischemic 53%) implanted with a single chamber ICD were followed for a median period of 847 [666–1030] days: 44 (27%) had VT/VF episodes. Among a total of 706 VT/VF episodes, 623 were treated with ATP and/or shock. 7 patients were treated with shock as first delivered therapy (efficacy 100%), whereas 33 were treated with ATP (efficacy 55% of treated patients, 71% of episodes). The median cycle of the treated arrhythmias was 309 [280–324] ms.
Efficacy at first attempt ALL Ischemic NICM Primary Secondary Per patient (first therapy occurrence) Shock (7/7) 100% (7/7) 100% – (6/6) 100% (1/1) 100% ATP (18/33) 55% (13/23) 57% (5/10) 50% (13/22) 59% (5/11) 45% Per episode Shock (14/14) 100% (14/14) 100% – (6/6) 59% (8/8) 100% ATP (432/609) 71% (245/362) 68% (187/247) 76% (127/201) 63% (305/408) 75%
Conclusion
ATP is quite effective is a contemporary cohort of single chamber ICD recipients in a fast arrhythmia range (average 190–220 bpm) with a long detection. This observation strengthen the value of ATP in ICD selection, and should be balancen when considering an S-ICD.
Collapse
Affiliation(s)
- A Angeletti
- University Hospital Policlinic S. Orsola-Malpighi, Bologna, Italy
| | - P Paolisso
- University Hospital Policlinic S. Orsola-Malpighi, Bologna, Italy
| | - G Statuto
- University Hospital Policlinic S. Orsola-Malpighi, Bologna, Italy
| | - G Massaro
- University Hospital Policlinic S. Orsola-Malpighi, Bologna, Italy
| | - S Lorenzetti
- University Hospital Policlinic S. Orsola-Malpighi, Bologna, Italy
| | - J Frisoni
- University Hospital Policlinic S. Orsola-Malpighi, Bologna, Italy
| | - C Martignani
- University Hospital Policlinic S. Orsola-Malpighi, Bologna, Italy
| | - M Ziacchi
- University Hospital Policlinic S. Orsola-Malpighi, Bologna, Italy
| | - D Giacopelli
- University Hospital Policlinic S. Orsola-Malpighi, Bologna, Italy
| | - D Grassini
- University Hospital Policlinic S. Orsola-Malpighi, Bologna, Italy
| | - I Diemberger
- University Hospital Policlinic S. Orsola-Malpighi, Bologna, Italy
| | - M Biffi
- University Hospital Policlinic S. Orsola-Malpighi, Bologna, Italy
| |
Collapse
|
26
|
Diemberger I, Martignani C, Massaro G, Lorenzetti S, De Bie J. P2840Discrimination between sinus rhythm and atrial fibrillation/flutter: reliability of seven different built-in automatic-diagnostic computer programs in a cohort of >2000 12-lead electrocardiograms. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.1150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Introduction
Atrial fibrillation and flutter (AF/AFl) are the more common sustained arrhythmias in the elderly. ESC guidelines underline the need for large-scale screening strategies, especially to improve primary prevention of thromboembolic complications. However, the current gold-standard for identification of AF/AFl is a 12-lead ECG reviewed by an appropriately trained physician. The availability of automatic discrimination between AF/AFl and sinus rhythm (SR) by automatic- diagnostic computer programs (ACP) implemented in current 12-lead ECG recorders is a possible solution to improve this process.
Aim
To assess the reliability and agreement of the main world-wide available ACPs implemented in current 12-lead ECG recorders in discriminating between AF/AFl vs. SR in a large dataset of real-world ECGs.
Methods
We assessed seven ECG interpretation programs from seven different manufacturers (GE 12SL, Glasgow, MEANS, Midmark, Mortara VERITAS, Philips DXL and Schiller). We created a large set of representative ECGs converted from previously recorded digital ECGs acquired with equipment that complied with the requirements of International Electrotechnical Commission standard IEC 60601–2-51:2003 and were representative of those in hospital settings. We excluded ECGs from pacemaker carriers. We used a specific device for playing back ECGs to 12-lead ECG recorders implementing the seven programs. Each statement from automatic diagnosis provided by each device was recorded and combined appropriately for the purpose of this analysis: identification of AF/AFl vs. SR. Gold standard was built by independent re-assessment by three different reviewers.
Results
We collected 2064 10s 12-lead ECGs with SR (1882) or AF/AFl (182) that were analyzed by seven different ACP. ECG's with other arrhythmias were excluded for this analysis (to increase transferability of the results). All seven programs agreed on SR in 1645 (87.4%) and AF/AFl in 139 cases (76.4%) (Figure 1, panel A). In 280 cases (13.6%), at least one program did not agree with the others. After revision by cardiologists 237 were found to be SR and 43 AF/AFl. Sensitivity for AF/AFl ranged between 90%-97% and false positive diagnosis ranged between 3.4% and 0.4%. Notably, the chance of obtaining at least a wrong diagnosis from one device was 280/2064 (13.6%), with a number of possible false AF/AFl greater than real prevalence of AF/AFl (Figure 1, panel B).
Figure 1
Conclusions
Despite a general good reliability of each single ACP for AF/AFl recognition the chance of between-device discordance is not negligible and the risk of false positive automatic diagnosis of AF/AFl should be considered when managing real-world patients especially when deciding to start oral anticoagulation.
Collapse
Affiliation(s)
- I Diemberger
- Institute of Cardiology University of Bologna, Bologna, Italy
| | - C Martignani
- Institute of Cardiology University of Bologna, Bologna, Italy
| | - G Massaro
- Institute of Cardiology University of Bologna, Bologna, Italy
| | - S Lorenzetti
- Institute of Cardiology University of Bologna, Bologna, Italy
| | - J De Bie
- Mortara Instrument Europe s.r.l., Bologna, Italy
| |
Collapse
|
27
|
Boriani G, Proietti M, Laroche C, Diemberger I, Kalarus Z, Potpara T, Fauchier L, Crijns HJGM, Maggioni A, Lip GYH. P3784Impact of progressively impaired renal function on major adverse outcomes in European patients with atrial fibrillation: a report from the ESC EORP-AF long-term general registry. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0633] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Renal function is an important predictor of major adverse outcomes in the general population. In the setting of atrial fibrillation (AF), renal dysfunction may act both as a risk factor and a proxy of vascular risk factors and comorbidities.
Methods
We analyzed the association of renal function, as estimated glomerular filtration rate (eGFR) using the CKD-EPI formula, with 1-year outcomes in a “real-world” cohort of European AF patients from the EORP-AF Long-Term General Registry.
Results
7725 were available for this analysis. Of these, 1294 (16.7%) had normal renal function (≥90 mL/min/1.73 m2), 3848 (49.8%) mildly reduced renal function (60–89 mL/min/1.73 m2), 2311 (29.9%) moderately reduced renal function (30–59 mL/min/1.73 m2) and 272 (3.5%) severely reduced renal function (<30 mL/min/1.73 m2). CHA2DS2-VASc and HAS-BLED scores values increased across eGFR strata (p<0.0001). Among patients qualifying for oral anticoagulant (OAC) therapy, those with severely impaired renal function were less often prescribed with any OAC (79.8%, p<0.0001), more likely with vitamin K antagonist (62.9%) than non-vitamin K antagonist oral anticoagulants (16.9%) (p<0.0001). At 1-year follow-up the rates of any thromboembolic event (TE)/acute coronary syndrome (ACS)/cardiovascular (CV) death progressively increased with worsening renal function, up to 20.7% in patients with severe dysfunction (p<0.0001). Rates of CV death and all-cause death were higher in severe renal dysfunction (16.9% and 21.3%; p<0.0001). Cox regression analysis (adjusted for known predictors) showed that eGFR <30 mL/min/1.73 m2, compared to normal renal function was associated with an increased risk of all the adverse outcomes (Table). eGFR decrease by 10 mL/min/1.73 m2 was associated with increased risks (Table).
Any TE/ACS/CV Death CV Death All-Cause Death mL/min/1.73 m2 HR (95% CI) HR (95% CI) HR (95% CI) eGFR ≥90 (ref.) – – – eGFR 60–89 0.99 (0.67–1.46) 0.81 (0.44–1.51) 0.74 (0.47–1.19) eGFR 30–50 1.12 (0.74–1.69) 1.00 (0.53–1.89) 0.95 (0.59–1.54) eGFR <30 2.47 (1.52–3.99) 2.73 (1.36–5.49) 2.16 (1.25–3.72) eGFR (by 10 mL/min/1.73 m2 decrease) 1.11 (1.05–1.17) 1.18 (1.10–1.27) 1.11 (1.03–1.18) ACS = Acute coronary syndrome; CI = Confidence interval; CV = Cardiovascular; eGFR = estimated Glomerular Filtration Rate; HR = Hazard ratio; TE = Thromboembolic event.
Conclusions
In AF patients, impaired renal function at baseline is associated with a progressive increase in the risk of major adverse outcomes during follow up. Severe renal dysfunction is an independent predictor of all the adverse outcomes.
Collapse
Affiliation(s)
- G Boriani
- University of Modena & Reggio Emilia, Department of Biomedical, Metabolic and Neural Sciences, Modena, Italy
| | - M Proietti
- The Mario Negri Institute for Pharmacological Research, Milan, Italy
| | - C Laroche
- European Society of Cardiology, EURObservational Research Programme Department, Sophia-Antipolis, France
| | - I Diemberger
- University of Bologna, Department of Experimental, Diagnostic and Specialty Medicine, Bologna, Italy
| | - Z Kalarus
- Silesian Center for Heart Diseases (SCHD), Zabrze, Poland
| | - T Potpara
- University of Belgrade, School of Medicine, Belgrade, Serbia
| | - L Fauchier
- University F. Rabelais of Tours, Centre Hospitalier Universitaire Trousseau et Faculté de Médecine, Tours, France
| | - H J G M Crijns
- Maastricht University Medical Centre (MUMC), Department of Cardiology, Maastricht, Netherlands (The)
| | - A Maggioni
- ANMCO Foundation For Your Heart, Florence, Italy
| | - G Y H Lip
- University of Liverpool, Liverpool Centre for Cardiovascular Science, Liverpool, United Kingdom
| |
Collapse
|
28
|
Diemberger I, Massaro G, Martignani C, Angeletti A, De Bie J. P3749Discrimination between normal and abnormal electrocardiograms: agreement of seven built-in automatic diagnostic programs in a cohort of >2000 12-lead traces. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0601] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Introduction
12-lead ECG is a standard evaluation for any patient admitted to a clinic but also for population screenings program and athlete periodical evaluation. Definition of a normal vs. abnormal ECG is a hard task and carefully trained physicians are needed to avoid inappropriate second level evaluations driven from a claim for ECG abnormality. Almost all current 1ECG recorders provide automatic diagnosis through built-in automatic-diagnostic computer programs (ACP). However, we have limited data comparing different ACP's in discriminating between normal and abnormal ECGs.
Aim
To assess the agreement of the main world-wide available automatic diagnostic programs implemented in current ECG recorders in discriminating between “normal” vs. “abnormal” ECGs in a large dataset of real-world ECGs.
Methods
We assessed seven ECG interpretation programs from seven different manufacturers (GE 12SL, Glasgow, MEANS, Midmark, Mortara VERITAS, Philips DXL and Schiller). We created a large set of representative ECGs converted from previously recorded digital ECGs acquired with equipment that complied with the requirements of International Electrotechnical Commission standard IEC 60601–2-51:2003 and were representative of those in hospital settings. We decided to exclude ECGs from pacemaker carriers. We used a specific device for playing back ECGs to 12-lead ECG recorders in appropriately setting to avoid interferences. Each statement from automatic diagnosis provided by each device was recorded and combined appropriately for the purpose of this analysis, identifying three group of ECGs: abnormal/substantially abnormal (ABN), normal/substantially normal (NRM) and borderline.
Results
2155 ECGs of 10s duration were analyzed by the 7 different ACPs: 513 from a pediatric population and 1642 from patients >16 years old consecutively collected mainly in hospital settings. Figure 1 evidences the prevalence of normal to abnormal grading according to each ACP in both groups of ECGs. Focusing in adult group we found that a NRM diagnosis was reported in a range of 129 (7.9%) to 478 (29.1%) among 1642 adult ECGs. On the contrary, ABN statement was reported in a range of 774 (47.1%) to 1271 (77.4%). Notably, agreement between the 7 ACPs was present in 36 ECGs (2.2%) for NRM diagnosis, while the agreement for ABN diagnosis was present in 661 (40.3%) of the ECGs. We performed a sensitivity analysis by repeating the same calculation after taking out one of the device at turn reaching a maximum of 6.5% for NRM and 41.2%% for ABN diagnosis with 6/6 agreement.
Figure 1
Conclusions
In our large cohort of almost unselected hospital ECGs the agreement on “normal” and “abnormal” among programs of different manufacturers is rather low. This should be carefully considered when using automatic ACP diagnosis as a screening or priority tool for ECG interpretation. Tailor-made review by physicians is still necessary for both clinical and research purposes.
Collapse
Affiliation(s)
- I Diemberger
- Institute of Cardiology University of Bologna, Bologna, Italy
| | - G Massaro
- Institute of Cardiology University of Bologna, Bologna, Italy
| | - C Martignani
- Institute of Cardiology University of Bologna, Bologna, Italy
| | - A Angeletti
- Institute of Cardiology University of Bologna, Bologna, Italy
| | - J De Bie
- Mortara Instrument Europe s.r.l., Bologna, Italy
| |
Collapse
|
29
|
Ziacchi M, Diemberger I, Corzani A, Martignani C, Mazzotti A, Massaro G, Valzania C, Rapezzi C, Boriani G, Biffi M. Cardiac resynchronization therapy: a comparison among left ventricular bipolar, quadripolar and active fixation leads. Sci Rep 2018; 8:13262. [PMID: 30185834 PMCID: PMC6125407 DOI: 10.1038/s41598-018-31692-z] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2018] [Accepted: 08/08/2018] [Indexed: 11/09/2022] Open
Abstract
We evaluated the performance of 3 different left ventricular leads (LV) for resynchronization therapy: bipolar (BL), quadripolar (QL) and active fixation leads (AFL). We enrolled 290 consecutive CRTD candidates implanted with BL (n = 136) or QL (n = 97) or AFL (n = 57). Over a minimum 10 months follow-up, we assessed: (a) composite technical endpoint (TE) (phrenic nerve stimulation at 8 V@0.4 ms, safety margin between myocardial and phrenic threshold <2V, LV dislodgement and failure to achieve the target pacing site), (b) composite clinical endpoint (CE) (death, hospitalization for heart failure, heart transplantation, lead extraction for infection), (c) reverse remodeling (RR) (reduction of end systolic volume >15%). Baseline characteristics of the 3 groups were similar. At follow-up the incidence of TE was 36.3%, 14.3% and 19.9% in BL, AFL and QL, respectively (p < 0.01). Moreover, the incidence of RR was 56%, 64% and 68% in BL, AFL and QL respectively (p = 0.02). There were no significant differences in CE (p = 0.380). On a multivariable analysis, "non-BL leads" was the single predictor of an improved clinical outcome. QL and AFL are superior to conventional BL by enhancing pacing of the target site: AFL through prevention of lead dislodgement while QL through improved management of phrenic nerve stimulation.
Collapse
Affiliation(s)
- M Ziacchi
- Institute of Cardiology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Policlinico S.Orsola-Malpighi, Bologna, Italy.
| | - I Diemberger
- Institute of Cardiology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Policlinico S.Orsola-Malpighi, Bologna, Italy
| | - A Corzani
- Institute of Cardiology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Policlinico S.Orsola-Malpighi, Bologna, Italy
| | - C Martignani
- Institute of Cardiology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Policlinico S.Orsola-Malpighi, Bologna, Italy
| | - A Mazzotti
- Institute of Cardiology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Policlinico S.Orsola-Malpighi, Bologna, Italy
| | - G Massaro
- Institute of Cardiology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Policlinico S.Orsola-Malpighi, Bologna, Italy
| | - C Valzania
- Institute of Cardiology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Policlinico S.Orsola-Malpighi, Bologna, Italy
| | - C Rapezzi
- Institute of Cardiology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Policlinico S.Orsola-Malpighi, Bologna, Italy
| | - G Boriani
- Institute of Cardiology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Policlinico S.Orsola-Malpighi, Bologna, Italy
- Cardiology Division. Department of Diagnostics, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy
| | - M Biffi
- Institute of Cardiology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Policlinico S.Orsola-Malpighi, Bologna, Italy
| |
Collapse
|
30
|
Boriani G, Proietti M, Laroche C, Diemberger I, Rheinert C, Serdechnaya EV, Diker E, Maggioni AP, Lip GYH. P3475Relationship between age and use of oral anticoagulant drugs in european atrial fibrillation patients: the EORP-AF general long-term registry. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p3475] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- G Boriani
- University of Modena & Reggio Emilia, Cardiology Department, Modena, Italy
| | - M Proietti
- University of Birmingham, Institute of Cardiovascular Sciences, Birmingham, United Kingdom
| | - C Laroche
- European Society of Cardiology, EURObservational Research Programme Department, Sophia-Antipolis, France
| | - I Diemberger
- University Hospital Policlinic S. Orsola-Malpighi, Experimental, Diagnostic and Specialty Medicine, Bologna, Italy
| | - C Rheinert
- Schwemlinger Gemeinschaftspraxis, Merzig/Saar, Germany
| | - E V Serdechnaya
- Northern State Medical University, Arkhangelsk, Russian Federation
| | - E Diker
- Medicana Hospital, Department of Cardiology, Ankara, Turkey
| | - A P Maggioni
- ANMCO Foundation For Your Heart, Florence, Italy
| | - G Y H Lip
- University of Birmingham, Institute of Cardiovascular Sciences, Birmingham, United Kingdom
| | | |
Collapse
|
31
|
Dell'era G, Erbetta R, Ziacchi M, Varalda M, Diemberger I, Prenna E, Guerra F, Biffi M, Occhetta E. P2928External implantable defibrillator as a bridge to reimplant after explant for infection: experience from two centers. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.p2928] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- G Dell'era
- University of Eastern Piedmont, Cardiology, Novara, Italy
| | - R Erbetta
- University of Eastern Piedmont, Cardiology, Novara, Italy
| | - M Ziacchi
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Bologna, Italy
| | - M Varalda
- University of Eastern Piedmont, Cardiology, Novara, Italy
| | - I Diemberger
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Bologna, Italy
| | - E Prenna
- University of Eastern Piedmont, Cardiology, Novara, Italy
| | - F Guerra
- University Hospital Riuniti of Ancona, Cardiology and Arrhythmology Clinic, Ancona, Italy
| | - M Biffi
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Bologna, Italy
| | - E Occhetta
- University of Eastern Piedmont, Cardiology, Novara, Italy
| |
Collapse
|
32
|
Diemberger I, Stefano L, Massaro G, Frisoni J, Angeletti A, Martignani C, Ziacchi M, Statuto G, Biffi M. P4854Predictors od ghosts after transvenous lead extraction for CIED infection. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p4854] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- I Diemberger
- Institute of Cardiology, Department of Experimental, Diagnostic and Specialty Medicine, Bologna, Italy
| | - L Stefano
- Institute of Cardiology, Department of Experimental, Diagnostic and Specialty Medicine, Bologna, Italy
| | - G Massaro
- Institute of Cardiology, Department of Experimental, Diagnostic and Specialty Medicine, Bologna, Italy
| | - J Frisoni
- Institute of Cardiology, Department of Experimental, Diagnostic and Specialty Medicine, Bologna, Italy
| | - A Angeletti
- Institute of Cardiology, Department of Experimental, Diagnostic and Specialty Medicine, Bologna, Italy
| | - C Martignani
- Institute of Cardiology, Department of Experimental, Diagnostic and Specialty Medicine, Bologna, Italy
| | - M Ziacchi
- Institute of Cardiology, Department of Experimental, Diagnostic and Specialty Medicine, Bologna, Italy
| | - G Statuto
- Institute of Cardiology, Department of Experimental, Diagnostic and Specialty Medicine, Bologna, Italy
| | - M Biffi
- Institute of Cardiology, Department of Experimental, Diagnostic and Specialty Medicine, Bologna, Italy
| |
Collapse
|
33
|
Segreti L, Migliore F, Diemberger I, Tola G, Pisano' E, Piro A, Bertero G, Luzzi G, Rordorf R, Nigro G, Forleo GB, D'Onofrio A, Dello Russo A, Lovecchio M, Bongiorni MG. P2927Use of subcutaneous ICD after transvenous ICD extraction: an analysis of Italian clinical practice. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.p2927] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- L Segreti
- Azienda Ospedaliero - Universitaria Pisana, Pisa, Italy
| | - F Migliore
- University Hospital of Padova, Padua, Italy
| | | | - G Tola
- G. Brotzu Hospital, Cagliari, Italy
| | | | - A Piro
- Umberto I Polyclinic of Rome, Rome, Italy
| | | | - G Luzzi
- Polyclinic Hospital of Bari, Bari, Italy
| | - R Rordorf
- Policlinic Foundation San Matteo IRCCS, Pavia, Italy
| | - G Nigro
- Second University of Naples, Naples, Italy
| | | | - A D'Onofrio
- AO dei Colli-Monaldi Hospital, Naples, Italy
| | | | | | - M G Bongiorni
- Azienda Ospedaliero - Universitaria Pisana, Pisa, Italy
| |
Collapse
|
34
|
Finocchiaro G, Tanzarella G, Papadakis M, Dhutia H, Tome M, Diemberger I, Behr ER, Sharma S, Sheppard MN. 1000Sudden cardiac death in elderly patients with hypertrophic cardiomyopathy. data from a large pathology registry. Europace 2018. [DOI: 10.1093/europace/euy015.549] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- G Finocchiaro
- St George's University of London, London, United Kingdom
| | - G Tanzarella
- St George's University of London, London, United Kingdom
| | - M Papadakis
- St George's University of London, London, United Kingdom
| | - H Dhutia
- St George's University of London, London, United Kingdom
| | - M Tome
- St George's University of London, London, United Kingdom
| | | | - E R Behr
- St George's University of London, London, United Kingdom
| | - S Sharma
- St George's University of London, London, United Kingdom
| | - M N Sheppard
- St George's University of London, London, United Kingdom
| |
Collapse
|
35
|
Migliore F, Cataldi C, Mazzone P, Ferretto S, Diemberger I, China P, De Lazzari M, Peruzza F, Iliceto S, Bertaglia E. P922Transcatheter cardiac pacemaker implantation after lead extraction in pacemaker dependent patients and device infection: results from a multicentre italian registry. Europace 2018. [DOI: 10.1093/europace/euy015.523] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- F Migliore
- Departement of Cardiac, Thoracic and Vascular Sciences, University of Padova, Padova, Italy
| | - C Cataldi
- Departement of Cardiac, Thoracic and Vascular Sciences, University of Padova, Padova, Italy
| | - P Mazzone
- San Raffaele Hospital of Milan (IRCCS), Department of Cardiology and Cardiothoracic Surgery, Milan, Italy
| | - S Ferretto
- Departement of Cardiac, Thoracic and Vascular Sciences, University of Padova, Padova, Italy
| | - I Diemberger
- University Hospital Policlinic S. Orsola-Malpighi, Department of Experimental, Diagnostic and Specialty Medicine, Institute of Cardiology, Bologna, Italy
| | - P China
- Hospital dell'Angelo, Department of Cardiothoracic and Vascular Medicine, Mestre-Venice, Italy
| | - M De Lazzari
- Departement of Cardiac, Thoracic and Vascular Sciences, University of Padova, Padova, Italy
| | - F Peruzza
- Departement of Cardiac, Thoracic and Vascular Sciences, University of Padova, Padova, Italy
| | - S Iliceto
- Departement of Cardiac, Thoracic and Vascular Sciences, University of Padova, Padova, Italy
| | - E Bertaglia
- Departement of Cardiac, Thoracic and Vascular Sciences, University of Padova, Padova, Italy
| |
Collapse
|
36
|
Poluzzi E, Diemberger I, De Ridder M, Koci A, Clo M, Oteri A, Pecchioli S, Bezemer I, Schink T, Pilgaard Ulrichsen S, Boriani G, Sturkenboom MCJ, De Ponti F, Trifirò G. Use of antihistamines and risk of ventricular tachyarrhythmia: a nested case-control study in five European countries from the ARITMO project. Eur J Clin Pharmacol 2017; 73:1499-1510. [PMID: 28831527 DOI: 10.1007/s00228-017-2317-0] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2017] [Accepted: 08/03/2017] [Indexed: 11/29/2022]
Abstract
PURPOSE After regulatory restrictions for terfenadine and astemizole in '90s, only scarce evidence on proarrhythmic potential of antihistamines has been published. We evaluate the risk of ventricular tachyarrhythmia (VA) related to the use of individual antihistamines. METHODS A matched case-control study nested in a cohort of new users of antihistamines was conducted within the EU-funded ARITMO project. Data on 1997-2010 were retrieved from seven healthcare databases: AARHUS (Denmark), GEPARD (Germany), HSD and ERD (Italy), PHARMO and IPCI (Netherlands) and THIN (UK). Cases of VA were selected and up to 100 controls were matched to each case. The odds ratio (OR) of current use for individual antihistamines (AHs) was estimated using conditional logistic regression. RESULTS For agents largely used to prevent allergic symptoms, such as cetirizine, levocetirizine, loratadine, desloratadine and fexofenadine, we found no VA risk. A statistically significant, increased risk of VA was found only for current use of cyclizine in the pooled analysis (ORadj, 5.3; 3.6-7.6) and in THIN (ORadj, 5.3; 95% CI, 3.7-7.6), for dimetindene in GEPARD (ORadj, 3.9; 1.1-14.7) and for ebastine in GEPARD (ORadj, 3.3; 1.1-10.8) and PHARMO (ORadj, 4.6; 1.3-16.2). CONCLUSIONS The risk of VA associated with a few specific antihistamines could be ascribable to heterogeneity in pattern of use or in receptor binding profile.
Collapse
Affiliation(s)
- Elisabetta Poluzzi
- Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
| | - I Diemberger
- Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy
| | - M De Ridder
- Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands
| | - A Koci
- Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy
| | - M Clo
- Regione Emilia Romagna Health Authority, Bologna, Italy
| | - A Oteri
- Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.,Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy
| | - S Pecchioli
- Health Search, Italian College of General Practitioners, Florence, Italy.,Regional Agency for Healthcare Services of Tuscany, Florence, Italy
| | - I Bezemer
- PHARMO Institute for Drug Outcomes Research, Utrecht, Netherlands
| | - T Schink
- Leibniz Institute for Epidemiology and Prevention Research - BIPS, Bremen, Germany
| | - S Pilgaard Ulrichsen
- Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark
| | - G Boriani
- Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.,Cardiology Division, Department of Diagnostics, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy
| | - M C J Sturkenboom
- Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands
| | - F De Ponti
- Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy
| | - G Trifirò
- Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.,Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy
| |
Collapse
|
37
|
Ziacchi M, Corzani A, Diemberger I, Martignani C, Mazzotti A, Massaro G, Valzania C, Rapezzi C, Boriani G, Biffi M. P1505Cardiac resynchronization therapy: a comparison among left ventricular bipolar, quadripolar and active fixation leads. Europace 2017. [DOI: 10.1093/ehjci/eux158.131] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
38
|
Abstract
Asymptomatic atrial fibrillation (AF) is common and in view of its prognostic impact (the same as of clinically overt AF) knowledge of the overall AF burden (defined as the amount of time spent in AF) appears to be important, both for scientific and clinical reasons. Data collected on more than 12,000 patients indicate that cardiac implantable electrical devices (CIEDs) are validated tools for measuring AF burden and that AF burden is associated with an increased risk of stroke. A maximum daily AF burden of ≥ 1 h carries important negative prognostic implications and may be a clinically relevant parameter for improving risk stratification for stroke. Decision-making should primarily consider the context in which asymptomatic, subclinical arrhythmias are detected (i.e. primary or secondary prevention of stroke and systemic embolism) and the risk profile of every individual patient with regard to thromboembolic and haemorrhagic risk, as well as patient preferences and values. Continuous monitoring using CIEDs with extensive data storage capabilities allow in-depth study of the temporal relationship between AF and ischaemic stroke. The relationships between AF and stroke are complex. AF is certainly a risk factor for cardioembolic stroke, with a cause-effect relationship between the arrhythmia and a thromboembolic event, the latter being related to atrial thrombi. However, AF can also be a simple 'marker of risk', with a non-causal association between the arrhythmia and stroke, the latter being possibly related to atheroemboli from the aorta, the carotid arteries or from other sources.
Collapse
Affiliation(s)
- G Boriani
- Department of Experimental, Diagnostic and Specialty Medicine, Institute of Cardiology, University of Bologna, S. Orsola-Malpighi University Hospital, Bologna, Italy
| | | | | | | | | | | | | | | |
Collapse
|
39
|
Biffi M, Bertini M, Ziacchi M, Diemberger I, Martignani C, Boriani G. Left ventricular lead stabilization to retain cardiac resynchronization therapy at long term: when is it advisable? Europace 2013; 16:533-40. [DOI: 10.1093/europace/eut300] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
|
40
|
Boriani G, Biffi M, Diemberger I, Cervi E, Martignani C. Peri-operative management of patients taking antithrombotic therapy: need for an integrated proactive approach. Int J Clin Pract 2011; 65:236-9. [PMID: 21314860 DOI: 10.1111/j.1742-1241.2010.02553.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
41
|
Diemberger I, Biffi M, Martignani C, Boriani G. Delayed asymptomatic migration of an implantable cardioverter-defibrillator lead to the costophrenic angle. Europace 2010; 12:1126-1126. [DOI: 10.1093/europace/euq122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/30/2023] Open
|
42
|
Boriani G, Biffi M, Martignani C, Diemberger I, Valzania C, Bertini M, Branzi A. Expenditure and value for money: the challenge of implantable cardioverter defibrillators. QJM 2009; 102:349-56. [PMID: 19276209 DOI: 10.1093/qjmed/hcp025] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
Many technology-driven interventions entail considerable financial cost, raising affordability issues. The implantable cardioverter defibrillator (ICD) is a case of an effective primary prevention intervention with high initial costs that is capable of delivering long-term population benefits. At first glance, such interventions may provoke diffidence, if not active resistance, due to the financial burdens which inevitably accompany their widespread adoption. In this article, we review the available economic tools that can help address the ICD cost issue. We think awareness of such knowledge may facilitate dialogues between physicians, administrators and policymakers, and help foster rational decision-making.
Collapse
Affiliation(s)
- G Boriani
- Institute of Cardiology, University of Bologna, Bologna, Italy.
| | | | | | | | | | | | | |
Collapse
|
43
|
Boriani G, Biffi M, Marziali A, Diemberger I, Martignani C. A changing scenario in the clinical use of implantable defibrillators: the need for long-term data on lead performance. Europace 2008; 11:1-3. [DOI: 10.1093/europace/eun339] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
44
|
Diemberger I, McCready J, Nunn L, Chow AW. Is atrial fibrillation with very short cycle length suitable for ablation? A case report. Europace 2008; 10:1336-9. [DOI: 10.1093/europace/eun189] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
45
|
Martignani C, Diemberger I, Biffi M, Valzania C, Bertini M, Domenichini G, Boriani G. Atrial fibrillation ablation: beyond electro-mechanical matters. Eur Heart J 2008; 29:2818-9; author reply 2819. [DOI: 10.1093/eurheartj/ehn403] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
46
|
Boriani G, Diemberger I, Biffi M, Domenichini G, Martignani C, Valzania C, Branzi A. Electrical cardioversion for persistent atrial fibrillation or atrial flutter in clinical practice: predictors of long-term outcome. Int J Clin Pract 2007; 61:748-56. [PMID: 17493088 DOI: 10.1111/j.1742-1241.2007.01298.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Despite the results of Atrial Fibrillation Follow-up Investigation of Rhythm Management and Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation trials, which favour a general shift in atrial fibrillation (AF) therapeutic approach towards control of ventricular rate, a strategy based on restoration of sinus rhythm could still play a role in selected patients at lower risk of AF recurrence. We explored possible predictors of relapses after external electrical cardioversion among patients with persistent AF or atrial flutter (AFL). We analysed the clinical characteristics and conventional echocardiographic parameters of patients with persistent AF/AFL enrolled in an institutional electrical cardioversion programme. Among 242 patients (AF/AFL, 195/47; mean age 62+/-13 years), sinus rhythm was restored in 215 (89%) and maintained in 73 (34%) at a follow-up of 930 days (median). No baseline clinical/echocardiographic variables predicted acute efficacy of cardioversion at logistic regression analysis. However, two variables predicted long-term AF/AFL recurrence among patients with successful cardioversion at multivariate Cox's proportional hazards analysis: (i) duration of arrhythmia>or=1 year (HR, 2.07; 95% CI, 1.29-3.33) and (ii) presence of previous cardioversion (HR, 1.67; 95% CI, 1.17-2.38). These variables also presented high-positive predictive values (72% and 80% respectively). Whereas the high acute efficacy of electrical cardioversion (approximately 90%) does not appear to be predictable, two simple clinical variables could help identify patients at higher risk of long-term AF/AFL recurrence after successful electrical cardioversion. We think there could be a case for initially attempting external electrical cardioversion to patients who have had AF/AFL for <1 year. In such patients, the chance of long-term success appears to be relatively high.
Collapse
Affiliation(s)
- G Boriani
- Institute of Cardiology, University of Bologna, Azienda Ospedaliera S. Orsola-Malpighi, Bologna, Italy.
| | | | | | | | | | | | | |
Collapse
|